[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1194
1. Niino D, Tsukasaki K, Torii K, Imanishi D, Tsuchiya T, Onimaru Y, Tsushima H, Yoshida S, Yamada Y, Kamihira S, Tomonaga M: Human herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia. Haematologica; 2008 Jan;93(1):e21-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass.
  • PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8).
  • However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.
  • [MeSH-major] Antigens, CD4 / biosynthesis. DNA-Binding Proteins / genetics. Gene Rearrangement. Herpesvirus 8, Human / genetics. Lymphoma, Primary Effusion / genetics. Lymphopenia / therapy. T-Lymphocytes / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / pharmacology. Dyspnea / diagnosis. HIV Infections / diagnosis. Humans. Immunophenotyping. Male. Pericardial Effusion


2. Martelli C, Alderighi D, Coronnello M, Dei S, Frosini M, Le Bozec B, Manetti D, Neri A, Romanelli MN, Salerno M, Scapecchi S, Mini E, Sgaragli G, Teodori E: N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors. J Med Chem; 2009 Feb 12;52(3):807-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new compounds showed a wide range of potencies and efficacies on doxorubicin-resistant erythroleukemia K562 cells in the pirarubicin uptake assay.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140665.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclohexanols; 0 / Cyclohexylamines; 0 / P-Glycoprotein; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


3. Wang W, Yao LB, Liu XP, Feng Q, Shang ZC, Cao YX, Sun BZ: Effects of STI571 and p27 gene clone on proliferation and apoptosis of K562 cells. World J Gastroenterol; 2005 Apr 14;11(14):2130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of STI571 and p27 gene clone on proliferation and apoptosis of K562 cells.
  • AIM: To investigate the combined effect of STI571 and p27 gene clone on the regulation of proliferation, cell cycle and apoptosis of K562 cell line.
  • METHODS: p27 gene was obtained by RT-PCR, and its sequence was approved to be correct.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Cycle Proteins / genetics. Genetic Therapy / methods. Leukemia, Erythroblastic, Acute / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15810079.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cell Cycle Proteins; 0 / Piperazines; 0 / Pyrimidines; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC4305782
  •  go-up   go-down


Advertisement
4. Szmigielski S, Sobiczewska E: [Risk of neoplastic diseases in conditions of exposure to power magnetic fields--epidemiologic investigations]. Med Pr; 2009;60(3):223-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk of neoplastic diseases in conditions of exposure to power magnetic fields--epidemiologic investigations].
  • Cancer risks of power magnetic fields are small and doubtful, but there exist confirmed epidemiologic investigations that in children living in homes where PMF intensity exceeds 0.3-0.4 microT (0.24-0.32 A/m) an increased risk of certain types of leukemias can be observed.
  • About one percent of children live under conditions of PMF exposure.
  • The authors also discuss the binding regulations on the protection of the general population and workers against power magnetic fields and they conclude that existing permissible exposure levels are incompatible with exposure conditions, the present state of knowledge and health threats.
  • [MeSH-major] Electromagnetic Fields / adverse effects. Electromagnetic Phenomena. Environmental Exposure / statistics & numerical data. Neoplasms / epidemiology. Neoplasms / etiology
  • [MeSH-minor] Adult. Brain Neoplasms / epidemiology. Brain Neoplasms / etiology. Causality. Child. Humans. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Lymphoma / epidemiology. Lymphoma / etiology. Poland / epidemiology. Risk Assessment / statistics & numerical data. Risk Factors. Soft Tissue Neoplasms / epidemiology. Soft Tissue Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19746891.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 35
  •  go-up   go-down


5. Blaybel R, Théoleyre O, Douablin A, Baklouti F: Downregulation of the Spi-1/PU.1 oncogene induces the expression of TRIM10/HERF1, a key factor required for terminal erythroid cell differentiation and survival. Cell Res; 2008 Aug;18(8):834-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of the Spi-1/PU.1 oncogene induces the expression of TRIM10/HERF1, a key factor required for terminal erythroid cell differentiation and survival.
  • Sustained expression of the Spi-1/PU.1 and Fli-1 oncoproteins blocks globin gene activation in mouse erythroleukemia cells; however, only Spi-1/PU.1 expression inhibits the inclusion of exon 16 in the mature 4.1R mRNA.
  • This report demonstrates that Spi-1/PU.1 downregulation induces the activation of TRIM10/hematopoietic RING finger 1 (HERF1), a member of the tripartite motif (TRIM)/RBCC protein family needed for globin gene transcription.
  • Additionally, we demonstrate that TRIM10/HERF1 is required for the regulated splicing of exon 16 during late erythroid differentiation.
  • Altogether, these data indicate that primary Spi-1/PU.1 downregulation acts on late erythroid differentiation through at least two pathways, one of which requires TRIM10/HERF1 upregulation and parallels the Spi-1/PU.1-induced Fli-1 shutoff regulatory cascade.
  • [MeSH-major] Cell Differentiation / genetics. Erythroid Cells / metabolism. Hematopoiesis / physiology. Histocompatibility Antigens / metabolism. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism

  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560381.001).
  • [ISSN] 1748-7838
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Carrier Proteins; 0 / Epb4.1 protein, mouse; 0 / Fli1 protein, mouse; 0 / Hemoglobins; 0 / Histocompatibility Antigens; 0 / Microfilament Proteins; 0 / Proto-Oncogene Protein c-fli-1; 0 / Proto-Oncogene Proteins; 0 / TRIM10 protein, human; 0 / TRIM10 protein, mouse; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


6. Cai Q, Verma SC, Choi JY, Ma M, Robertson ES: Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency. J Virol; 2010 Nov;84(21):11134-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the infectious viral agent associated with Kaposi's sarcoma and may also contribute to B-cell disorders, which include primary effusion lymphoma (PEL) and multicentric Castleman's disease.
  • In this report, we demonstrate that KSHV suppresses the interleukin-4 (IL-4)-stimulated immune response of B-lymphocyte activation and cell proliferation.
  • Importantly, knockdown of endogenous STAT6 dramatically increases the sensitivity of PEL cells to low-serum stress or chemical-mediated cellular apoptosis and reactivation of KSHV from latent replication.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Immunity. 1995 Jun;2(6):689-97 [7796300.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Nucleic Acids Res. 1995 Aug 11;23(15):2919-28 [7544888.001]
  • [Cites] Nature. 1996 Apr 18;380(6575):627-30 [8602263.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] Immunology. 1997 Jan;90(1):147-53 [9038725.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):147-53 [9224640.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2606-10 [9366576.001]
  • [Cites] Cell Res. 1998 Mar;8(1):1-13 [9570012.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5366-73 [9605136.001]
  • [Cites] J Hum Virol. 1997 Nov-Dec;1(1):19-29 [10195227.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Annu Rev Immunol. 1999;17:701-38 [10358772.001]
  • [Cites] J Surg Res. 2004 Nov;122(1):14-20 [15522309.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2067-75 [15688008.001]
  • [Cites] FEBS Lett. 2006 Jan 9;580(1):93-8 [16364321.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Jun;17(3):173-88 [16540365.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] Cancer Lett. 2006 Nov 8;243(1):38-46 [16387423.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] J Virol. 2007 Mar;81(5):2449-58 [17151100.001]
  • [Cites] J Virol. 2007 Mar;81(5):2401-17 [17151125.001]
  • [Cites] FASEB J. 2007 May;21(7):1433-44 [17283223.001]
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] Blood. 2008 May 1;111(9):4731-40 [18199825.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1424-33 [18541724.001]
  • [Cites] J Virol. 2008 Sep;82(17):8771-9 [18579585.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2106-10 [18401415.001]
  • [Cites] J Virol. 2009 May;83(10):5056-66 [19279093.001]
  • [Cites] Neoplasia. 2009 Dec;11(12):1272-84 [20019835.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Int Immunol. 2000 Jul;12(7):995-1003 [10882411.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] FEBS Lett. 2000 Nov 24;485(2-3):122-6 [11094153.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3076-84 [11753987.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27169-75 [12023955.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Blood. 2004 Jul 15;104(2):543-9 [15044251.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(7):2061-5 [3083412.001]
  • [Cites] Annu Rev Immunol. 1987;5:429-59 [3297106.001]
  • [Cites] Immunology. 1989 Jun;67(2):237-43 [2502496.001]
  • [Cites] J Immunol. 1990 Dec 1;145(11):3796-806 [2147202.001]
  • [Cites] J Immunol. 1991 Jan 15;146(2):592-8 [1702807.001]
  • [Cites] Blood. 1991 May 1;77(9):1859-70 [2018830.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1445-51 [2044655.001]
  • [Cites] J Immunol. 1992 Mar 15;148(6):1812-6 [1541822.001]
  • [Cites] Science. 1992 Jul 17;257(5068):379-82 [1631559.001]
  • [Cites] Int Immunol. 1993 Mar;5(3):293-301 [8466866.001]
  • [Cites] Science. 1993 Dec 17;262(5141):1877-80 [8266077.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1285-95 [7908323.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):181-92 [7807002.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):966-70 [7822337.001]
  • (PMID = 20719954.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA091792; United States / NIDCR NIH HHS / DE / DE014136; United States / NIDCR NIH HHS / DE / R01 DE014136; United States / NCI NIH HHS / CA / R00 CA126182-04; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / K99 CA126182; United States / NIAID NIH HHS / AI / AI067037; United States / NCI NIH HHS / CA / R00 CA126182; United States / NIAID NIH HHS / AI / R01 AI067037; United States / NIDCR NIH HHS / DE / R01 DE017338; United States / NCI NIH HHS / CA / CA126182; United States / NIDCR NIH HHS / DE / DE17338; United States / NCI NIH HHS / CA / CA126182-04; United States / NCI NIH HHS / CA / CA072510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT6 Transcription Factor; 0 / STAT6 protein, human; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ PMC2953196
  •  go-up   go-down


7. Cannon M, Cesarman E, Boshoff C: KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2. Blood; 2006 Jan 1;107(1):277-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.
  • Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is now known to be an etiologic force behind KS and primary-effusion lymphoma (PEL).
  • Over time, KSHV has pirated many human genes whose products regulate angiogenesis, inflammation, and the cell cycle.
  • Although it is considered a viral oncogene and causes KS-like lesions in mice, vGPCR expression results in cell-cycle arrest of KSHV-infected PEL cells.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1557-64 [8622872.001]
  • [Cites] Annu Rev Physiol. 1996;58:143-70 [8815789.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Virol. 1996 Nov;70(11):8218-23 [8892957.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Nature. 1997 Jan 23;385(6614):347-50 [9002520.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] J Virol. 1997 Mar;71(3):1963-74 [9032328.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Virology. 1997 Feb 17;228(2):371-8 [9123844.001]
  • [Cites] J Virol. 1997 Jun;71(6):4187-92 [9151804.001]
  • [Cites] J Virol. 1997 Jun;71(6):4791-7 [9151873.001]
  • [Cites] Virology. 1997 May 12;231(2):239-47 [9168886.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] J Virol. 2004 Jan;78(1):104-15 [14671092.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):514-23 [14724579.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] Agents Actions Suppl. 1998;49:5-13 [9426822.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:261-91 [9442875.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):801-6 [9480990.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1433-43 [9626048.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1469-72 [9788958.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):956-61 [9873037.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] Biochem J. 1999 Feb 1;337 ( Pt 3):607-16 [9895308.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 30;253(3):725-7 [9918794.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):280-9 [9925742.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):83-90 [9934688.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] J Pathol. 1999 Apr;187(5):582-7 [10398125.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Curr Biol. 1999 Oct 7;9(19):1075-84 [10531005.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6252-61 [10597223.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):445-54 [10662790.001]
  • [Cites] Virology. 2000 Feb 15;267(2):247-51 [10662620.001]
  • [Cites] Mol Pharmacol. 2000 Mar;57(3):602-9 [10692502.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Apr;9(2):137-45 [10813527.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3689-95 [10919634.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):624-35 [11134348.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1376-82 [11031271.001]
  • [Cites] J Virol. 2001 Mar;75(6):2866-78 [11222712.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1187-97 [11297694.001]
  • [Cites] J Virol. 2001 May;75(10):4475-81 [11312317.001]
  • [Cites] J Immunol. 2001 Jul 1;167(1):505-13 [11418689.001]
  • [Cites] Virology. 2001 Aug 15;287(1):62-70 [11504542.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):45979-87 [11590141.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1789-96 [11748262.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1823-31 [11896614.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Virol. 2003 Jan;77(1):57-67 [12477810.001]
  • [Cites] J Virol. 2003 Jan;77(2):851-61 [12502801.001]
  • [Cites] J Virol. 2003 Feb;77(4):2631-9 [12552002.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):23-36 [12559173.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):131-43 [12620408.001]
  • [Cites] FASEB J. 2004 Mar;18(3):422-7 [15003988.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3284-95 [14981547.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Mol Cell Biol. 1993 Feb;13(2):1194-201 [8423786.001]
  • [Cites] EMBO J. 1993 Feb;12(2):461-8 [8440237.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] J Biol Chem. 1993 Oct 5;268(28):20691-4 [8407886.001]
  • [Cites] Science. 1993 Dec 24;262(5142):2050-4 [8266103.001]
  • [Cites] Curr Opin Cell Biol. 1994 Apr;6(2):191-7 [8024809.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • (PMID = 16150942.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA068 939; United States / NIAID NIH HHS / AI / K08-AI53 971
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / G protein-coupled receptor, Human herpesvirus 8; 0 / Immediate-Early Proteins; 0 / Receptors, Chemokine; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  • [Other-IDs] NLM/ PMC1895347
  •  go-up   go-down


8. Kowalska K, Soscia C, Combe H, Vasseur P, Voulhoux R, Filloux A: The C-terminal amphipathic alpha-helix of Pseudomonas aeruginosa PelC outer membrane protein is required for its function. Biochimie; 2010 Jan;92(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biofilm formation results from the production of a matrix mainly comprised of exopolysaccharides. P. aeruginosa possesses several gene clusters which contribute to the formation of the matrix, including the pel genes.
  • Among the pel genes, pelC encodes an outer membrane protein, which may serve as a transporter of polysaccharide to the bacterial cell surface.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19853003.001).
  • [ISSN] 1638-6183
  • [Journal-full-title] Biochimie
  • [ISO-abbreviation] Biochimie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins
  •  go-up   go-down


9. Zhang K, Han W, Zhang R, Xu X, Pan Q, Hu X: Phenylobacterium zucineum sp. nov., a facultative intracellular bacterium isolated from a human erythroleukemia cell line K562. Syst Appl Microbiol; 2007 Apr;30(3):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenylobacterium zucineum sp. nov., a facultative intracellular bacterium isolated from a human erythroleukemia cell line K562.
  • A bacterial strain HLK1(T) was isolated from the human erythroleukemia cell line K562.
  • The type strain is HLK1(T) (=CGMCC 1.3786(T), DSM=18354).

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908113.001).
  • [ISSN] 0723-2020
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY628697/ DQ311665/ DQ311666
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; EC 5.99.1.3 / DNA Gyrase
  •  go-up   go-down


10. Abe K, Shimizu R, Pan X, Hamada H, Yoshikawa H, Yamamoto M: Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment. Exp Hematol; 2009 Apr;37(4):435-445.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment.
  • In Gata1.05 gene knockdown mice, Gata1 expression deteriorates to 5% of wild-type allelic expression, a level insufficient for supporting normal erythropoiesis and one that leads to accumulation of erythroid progenitors that are readily transformed into erythroblastic leukemia.
  • To delineate characteristics of leukemic stem cells (LSCs), we analyzed LSCs of Gata1.05 leukemia, which have a potential to reestablish leukemia in mice.
  • MATERIALS AND METHODS: Leukemic cells isolated from the first recipient mice of Gata1.05 leukemia cells were divided into two fractions using Hoechst dye.
  • Fractionated cells were transplanted into second recipient, or analyzed gene expression profiles and cell-cycle status.
  • However, expression of hematopoietic stem cell (HSC)-related genes was upregulated in the LSP cells.
  • CONCLUSION: Based on this observation, distinct self-renewal regulatory mechanisms in LSCs may be considered as one of the causes of worsening of the features of leukemia after injury and relapse.
  • [MeSH-major] Fluorouracil / pharmacology. GATA1 Transcription Factor / metabolism. Leukemia / drug therapy. Stem Cells / drug effects

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302918.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / Gata1 protein, mouse; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C, Pierimarchi P, Serafino A, Mastino A, Bistoni F, Romani L, Rasi G: Thymosin alpha 1: from bench to bedside. Ann N Y Acad Sci; 2007 Sep;1112:225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the initial dramatic effects, observed in a Lewis lung carcinoma animal model, using a combination of thymosin alpha 1 (Talpha1) and interferon (IFN) after cyclophosphamide, a number of other preclinical models in mice (Friend erythroleukemia and B16 melanoma) and in rats (DHD/K12 colorectal cancer liver metastasis) have confirmed the efficacy of the combination therapy with Talpha1 and either IFN or IL-2 plus chemotherapy.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Disease Models, Animal. Killer Cells, Natural / drug effects. Killer Cells, Natural / immunology. Mice. Rats

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600290.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / thymalfasin; 61512-21-8 / Thymosin
  •  go-up   go-down


12. Talasz H, Lindner HH, Sarg B, Helliger W: Histone H4-lysine 20 monomethylation is increased in promoter and coding regions of active genes and correlates with hyperacetylation. J Biol Chem; 2005 Nov 18;280(46):38814-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone H4-lysine 20 monomethylation is increased in promoter and coding regions of active genes and correlates with hyperacetylation.
  • In the case of H3-Lys(4), H3-Lys(9), H3-Lys(27), and H4-Lys(20), the degree of methylation was variable from the mono- to the di- or trimethylated state, each of which was presumed to be involved in the organization of chromatin and the activation or repression of genes.
  • Here we investigated the interplay between histone H4-Lys(20) mono- and trim-ethylation and H4 acetylation at induced (beta-major/beta-minor glo-bin), repressed (c-myc), and silent (embryonic beta-globin) genes during in vitro differentiation of mouse erythroleukemia cells.
  • By using chromatin immunoprecipitation, we found that the beta-major and beta-minor promoter and the beta-globin coding regions as well as the promoter and the transcribed exon 2 regions of the highly expressed c-myc gene were hyperacetylated and monomethylated at H4-Lys(20).
  • Although activation of the beta-globin gene resulted in an increase in hyperacetylated, monomethylated H4, down-regulation of the c-myc gene did not cause a decrease in hyperacetylated, monomethylated H4-Lys(20), thus showing a stable pattern of histone modifications.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. ISOBUTYRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166085.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butyrates; 0 / Chromatin; 0 / Cross-Linking Reagents; 0 / Heterochromatin; 0 / Histones; 0 / Isobutyrates; 0 / Proto-Oncogene Proteins c-myc; 1HG84L3525 / Formaldehyde; 8LL210O1U0 / isobutyric acid; 9004-22-2 / Globins; K3Z4F929H6 / Lysine
  •  go-up   go-down


13. Cohen R, Steinmaus C, Quinlan P, Ku R, Cooper M, Roberts T: Development of permissible exposure limits: the California experience. Int J Occup Environ Health; 2006 Jul-Sep;12(3):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of permissible exposure limits: the California experience.
  • The California OSHA Airborne Contaminant Advisory Committee reviewed several hundred substances and recommended occupational exposure limits with the intent of worker and employer protection.
  • [MeSH-major] Advisory Committees / organization & administration. Hazardous Substances / standards. Occupational Exposure / standards. Occupational Health / legislation & jurisprudence
  • [MeSH-minor] Animals. California. Communication. Humans. Maximum Allowable Concentration. National Institute for Occupational Safety and Health (U.S.) / standards. No-Observed-Adverse-Effect Level. Program Development. United States

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967831.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hazardous Substances
  •  go-up   go-down


14. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F: Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia; 2009 Dec;23(12):2275-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
  • Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis.
  • From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 were seen at the University of Texas-M.D.
  • Forty-five patients (50%) had a history of myelodysplatic syndrome (MDS), compared with 41% in our control group (patients with other AML subtypes) (P=0.08).
  • Poor-risk cytogenetics were more common in patients with AML-M6 (61% versus 38%, P=0.001).
  • Complete remission rates were 62% for patients with AML-M6, comparing with 58% for the control group (P=0.35).
  • Median disease free survival (DFS) for patients with AML-M6 was 32 weeks, versus 49 weeks for the control group (P=0.05).
  • Median overall survival (OS) of patients with AML-M6 was 36 weeks, compared with 43 weeks for the control group (P=0.60).
  • On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor.
  • AML-M6 is commonly associated with a previous diagnosis of MDS and poor-risk karyotype.
  • The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Myelodysplastic Syndromes / complications. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Acute Erythroleukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):34-40 [1615923.001]
  • [Cites] Blood. 1992 Oct 15;80(8):1869-79 [1391951.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2873-82 [1450412.001]
  • [Cites] Blood Rev. 1992 Dec;6(4):204-14 [1486289.001]
  • [Cites] Am J Hematol. 1995 May;49(1):29-38 [7741135.001]
  • [Cites] Br J Haematol. 1995 Aug;90(4):868-75 [7669665.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):42-7 [9499256.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):15-9 [9595039.001]
  • [Cites] Leuk Lymphoma. 1998 Jul;30(3-4):395-401 [9713970.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Am J Clin Pathol. 1998 Nov;110(5):590-8 [9802343.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):99-107 [10512167.001]
  • [Cites] Blood. 1958 Feb;13(2):192-4 [13510296.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Curr Opin Hematol. 2005 Jan;12(1):62-7 [15604893.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):113-22 [16337853.001]
  • [Cites] Blood. 1986 Nov;68(5):1167-74 [2945604.001]
  • [Cites] Acta Haematol. 1987;77(4):193-7 [3115028.001]
  • [Cites] Semin Oncol. 1987 Dec;14(4):425-34 [3321447.001]
  • [Cites] Leukemia. 1989 Apr;3(4):305-9 [2927179.001]
  • [Cites] Blood. 2006 Feb 1;107(3):880-4 [16123215.001]
  • [Cites] Am J Hematol. 2006 Jul;81(7):484-91 [16755568.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2314-21 [17158236.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):17-22 [16856158.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):346-55 [18692685.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Fall;11(3):348-59 [2675661.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):330-1 [10656753.001]
  • [Cites] Clin Lab Med. 2000 Mar;20(1):119-37 [10702900.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):5-13 [10936857.001]
  • [Cites] Intern Med. 2000 Oct;39(10):761-2 [11030195.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Pathol. 2001 Mar;54(3):205-9 [11253132.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):65-75 [11355924.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):737-45 [11380465.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):667-8 [11392312.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):451-5 [11398875.001]
  • [Cites] Haematologica. 2002 Feb;87(2):148-53 [11836165.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3135-40 [12384410.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):406-12 [12619165.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):939-43 [12648062.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1362-5 [14521454.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1276-86 [14970186.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 2):4833-7 [6945906.001]
  • [Cites] Blood. 1983 Apr;61(4):645-51 [6572533.001]
  • [Cites] Br J Haematol. 1990 Jul;75(3):346-54 [2386768.001]
  • (PMID = 19741728.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / U54 CA096300
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS636030; NLM/ PMC4217206
  •  go-up   go-down


15. Coyle AT, O'Keeffe MB, Kinsella BT: 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J; 2005 Sep;272(18):4754-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells.
  • In humans, thromboxane (TX) A2 signals through two receptor isoforms, thromboxane receptor (TP)alpha and TPbeta, which are transcriptionally regulated by distinct promoters, Prm1 and Prm3, respectively, within the single TP gene.
  • The aim of the current study was to investigate the ability of the endogenous peroxisome proliferator-activated receptor (PPAR)gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) to regulate expression of the human TP gene and to ascertain its potential effects on the individual TPalpha and TPbeta isoforms.
  • 15d-PGJ2 suppressed Prm3 transcriptional activity and TPbeta mRNA expression in the platelet progenitor megakaryocytic human erythroleukemia (HEL) 92.1.7 cell line but had no effect on Prm1 or Prm2 activity or on TPalpha mRNA expression.
  • 15d-PGJ2 also resulted in reductions in the overall level of TP protein expression and TP-mediated intracellular calcium mobilization in HEL cells.
  • These data provide direct evidence for the role of PPARgamma in the regulation of human TP gene expression within the vasculature and point to further critical differences in the modes of transcriptional regulation of TPalpha and TPbeta in humans.
  • Moreover, these data highlight a further link between enhanced risk of cardiovascular disease in diabetes mellitus associated with increased synthesis and action of thromboxane A2 (TXA2).
  • [MeSH-minor] Binding Sites. Cell Line, Tumor. Gene Expression Regulation. Humans. Leukemia, Erythroblastic, Acute / pathology. Ligands. Protein Isoforms. RNA, Messenger / analysis. RNA, Messenger / genetics. Response Elements

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156795.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 15-deoxy-delta(12,14)-prostaglandin J2; 0 / Ligands; 0 / PPAR gamma; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Thromboxane A2, Prostaglandin H2; RXY07S6CZ2 / Prostaglandin D2
  •  go-up   go-down


16. Azzini E, Vitaglione P, Intorre F, Napolitano A, Durazzo A, Foddai MS, Fumagalli A, Catasta G, Rossi L, Venneria E, Raguzzini A, Palomba L, Fogliano V, Maiani G: Bioavailability of strawberry antioxidants in human subjects. Br J Nutr; 2010 Oct;104(8):1165-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No quercetin and ACN were found in plasma, while coumaric acid, 4-hydroxybenzoic acid (4HBA, 56 and 54% of pelargonidin-3-glucoside (Pel-glc) ingested with FS and SS, respectively) and protocatechuic acid (59 and 34% of cyanidin-3-glucoside ingested with FS and SS, respectively) over 8 h from strawberry consumption were retrieved in the plasma.
  • Pelargonidin glucuronide, pelargonidin glucoside and pelargonidin aglycone peaked in urine within 2 h of strawberry consumption, and the 24 h amount excreted was always approximately 0.9% of the Pel-glc dose ingested.
  • Furthermore, in the present study, the metabolism of Pel-glc was elucidated, and, for the first time, 4HBA was suggested to be a major human metabolite of Pel-glc.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487578.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthocyanins; 0 / Antioxidants; 0 / Phenols; 36-88-4 / Carotenoids; 45XWE1Z69V / alpha-carotene
  •  go-up   go-down


17. Hancock D, Funnell A, Jack B, Johnston J: Introducing undergraduate students to real-time PCR. Biochem Mol Biol Educ; 2010 Sep;38(5):309-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The model used is a murine erythroleukemia cell line (MEL cells).
  • These continuously cycling, immature red blood cells, arrested at an early stage in erythropoiesis, can be induced to progress further through the process by 72 h exposure to 1.8% DMSO.
  • The relative levels of three sequences: β globin, amino levulinate synthase, and carbonic anhydrase-1 are estimated by real-time PCR, using 18S rRNA as the reference sequence.
  • The changes in gene expression are robust and reproducible, enabling students to experience a "cutting edge" research technique in an undergraduate lab setting.
  • While the undergraduate student experience in practical classes with such sensitive techniques is often mixed, the changes in gene expression in this model are sufficiently great that students can gain the satisfaction of consistent results.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 International Union of Biochemistry and Molecular Biology, Inc.
  • (PMID = 21567850.001).
  • [ISSN] 1539-3429
  • [Journal-full-title] Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology
  • [ISO-abbreviation] Biochem Mol Biol Educ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Patnayak R, Paul TR, Uppin SG, K G, Rajappa S, Rao DR: Acute erythroid leukemia (AML-M6) - Is it rare? Turk J Haematol; 2009 Mar 5;26(1):38-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute erythroid leukemia (AML-M6) - Is it rare?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265109.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


19. Das KC, Das M, Mohanty D, Jadaon MM, Gupta A, Marouf R, Easow SK: Megaloblastosis: from morphos to molecules. Med Princ Pract; 2005;14 Suppl 1:2-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Megaloblastosis (i.e., megaloblastic transformation of erythroid precursor cells in the bone marrow) is the cytomorphological hallmark of megaloblastic anemia resulting from vitamin B12 and folate deficiency.
  • RESULTS: Derangement of DNA synthesis occurred due to an impaired de novo pathway of thymidylate synthesis in both vitamin-B12- and folate-deficient human megaloblastic bone marrows as well as in the bone marrows of rhesus monkeys and rats with experimentally induced folate deficiency.
  • On the other hand, megaloblastic changes in the bone marrow of human patients with myelodysplastic syndrome and erythroleukemia were not associated with this DNA synthetic abnormality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 16103708.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Histones; 9007-49-2 / DNA
  •  go-up   go-down


20. Meier N, Krpic S, Rodriguez P, Strouboulis J, Monti M, Krijgsveld J, Gering M, Patient R, Hostert A, Grosveld F: Novel binding partners of Ldb1 are required for haematopoietic development. Development; 2006 Dec;133(24):4913-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It interacts with Gata1, Tal1, E2A and Lmo2 to form a transcription factor complex regulating late erythroid genes.
  • In accordance with the zebrafish results these factors are coexpressed in prehaematopoietic cells of the early mouse embryo, although we originally identified the complex in late erythroid cells.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cell Differentiation. Cell Line, Tumor. Chromatin Immunoprecipitation. Cyclin-Dependent Kinase 9 / metabolism. Erythroid Cells / cytology. Homeodomain Proteins / metabolism. LIM Domain Proteins. Leukemia, Erythroblastic, Acute. Mice. Nuclear Proteins / metabolism. Protein Binding. Repressor Proteins / metabolism. Transcription Factors / metabolism. Transfection. Zebrafish


21. Nakae K, Saito K, Iino T, Yamamoto N, Wakabayashi M, Yoshikawa S, Matsushima S, Miyashita H, Sugimoto H, Kiba A, Gupta J: A prostacyclin receptor antagonist inhibits the sensitized release of substance P from rat sensory neurons. J Pharmacol Exp Ther; 2005 Dec;315(3):1136-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. CHO Cells. Calcium / analysis. Calcium / metabolism. Cell Line, Tumor. Cells, Cultured. Cricetinae. Cyclic AMP / analysis. Dose-Response Relationship, Drug. Drug Interactions. Ganglia, Spinal / cytology. Ganglia, Spinal / drug effects. Ganglia, Spinal / enzymology. Ganglia, Spinal / metabolism. Humans. Iloprost / pharmacology. Inhibitory Concentration 50. K562 Cells. Kallidin / pharmacology. Leukemia, Erythroblastic, Acute / pathology. Molecular Structure. Osteosarcoma / pathology. Rats

  • Guide to Pharmacology. gene/protein/disease-specific - IP receptor - data and references .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109742.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Epoprostenol; 33507-63-0 / Substance P; 342-10-9 / Kallidin; E0399OZS9N / Cyclic AMP; JED5K35YGL / Iloprost; SY7Q814VUP / Calcium
  •  go-up   go-down


22. Herchel R, Sindelár Z, Trávnícek Z, Zboril R, Vanco J: Novel 1D chain Fe(III)-salen-like complexes involving anionic heterocyclic N-donor ligands. Synthesis, X-ray structure, magnetic, (57)Fe Mössbauer, and biological activity studies. Dalton Trans; 2009 Nov 28;(44):9870-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The iron(III) salen-type complexes [Fe(salen)(L)](n) (1-6) involving heterocyclic N-donor ligands HL {HL = 1H-imidazole (Himz), 1H-tetrazol-5-amine (Hatz), 5-methyl-1H-tetrazole (Hmtz), 1H-benzimidazole (Hbimz), 1H-1,2,4-triazole (Htriz) and 1H-benzotriazole (Hbtriz)} have been prepared and characterised by elemental analysis, FT IR, CI mass and (57)Fe Mössbauer spectroscopies, and variable temperature magnetic measurements.
  • The compounds have been tested for their SOD-like activity, DNA cleavage activity, and in vitro cytotoxicity against two human cancer cell lines: chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7).
  • [MeSH-minor] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Cell Line, Tumor. Crystallography, X-Ray. DNA Cleavage. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Ligands. Spectroscopy, Mossbauer. Superoxide Dismutase / pharmacology

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19885536.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Ligands; E1UOL152H7 / Iron; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


23. Drobot L, Husak Z, Ilnytska O, Igumentseva N, Oleksyn H, Kusen' S: Transient activation of Ras-dependent signalling at the early stages of Herbimycin A induced erythroid differentiation of human K562 cells. Exp Oncol; 2005 Mar;27(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient activation of Ras-dependent signalling at the early stages of Herbimycin A induced erythroid differentiation of human K562 cells.
  • AIM: To study the dynamics of Ras-dependent signalling in the course of Herbimycin A induced erythroid differentiation of human erythroleukemia K562 cells.
  • Transient rise of Ras-GTP level at 3rd h of incubation in the presence of Herbimycin A correlated with the increase in tyrosine phosphorylation of proteins with apparent molecular weight of 210, 160, 140, 116 and 42 kDa, as well as with the activation of Erk2 and increase of binding of a set of pY-containing proteins with recombinant GST-fusion form of Ras activator, adaptor protein Grb2.
  • CONCLUSION: The obtained results suggest that time-dependent changes in Grb2-mediated network of protein-protein interaction events might define implication of Ras-dependent signalling in Herbimycin A-induced erythroid differentiation of K562 cells.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Erythroid Cells / cytology. Proto-Oncogene Proteins p21(ras) / metabolism. Quinones / pharmacology. Signal Transduction / physiology

  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. RIFABUTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812354.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Benzoquinones; 0 / Enzyme Inhibitors; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; 0 / Lactams, Macrocyclic; 0 / Quinones; 146-91-8 / Guanosine Diphosphate; 1W306TDA6S / Rifabutin; 42HK56048U / Tyrosine; 70563-58-5 / herbimycin; 86-01-1 / Guanosine Triphosphate; EC 2.5.1.18 / Glutathione Transferase; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


24. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood; 2008 Mar 15;111(6):3183-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
  • MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of gene expression.
  • To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34(+) cells and 122 untreated adult AML cases using a microarray platform.
  • After background subtraction and normalization using a set of housekeeping genes, data were analyzed using Significance Analysis of Microarrays.
  • An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction.
  • We identified several miRNAs differentially expressed between CD34(+) normal cells and the AML samples. miRNA expression was also closely associated with selected cytogenetic and molecular abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-ITD mutations.
  • Furthermore, patients with high expression of miR-191 and miR-199a had significantly worse overall and event-free survival than AML patients with low expression (overall survival: miR-191, P = .03; and miR-199a, P = .001, Cox regression).
  • In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 Oct;18(10):1565-8 [15452588.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1550-7 [15973452.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):357-64 [12139719.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Biol Ther. 2003 Mar-Apr;2(2):164-70 [12750556.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] Blood. 1997 Jan 15;89(2):630-43 [9002967.001]
  • (PMID = 18187662.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / P01CA76259; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P01 CA076259; United States / NCI NIH HHS / CA / P01CA81534; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / P01 CA055164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2265455
  •  go-up   go-down


25. Karsten U, Butschak G, Stahn R, Goletz S: A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra- and intracellular epitopes. Int Immunopharmacol; 2010 Nov;10(11):1354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glycophorin A (GPA, CD235a) is a major membrane glycoprotein and marker of cells of the erythroid lineage.
  • The new panel complements the already known anti-glycophorin antibodies and offers several potential applications for, e.g., differential diagnosis of erythroleukemias, lineage analyses of erythroid cells, isolation of senescent erythrocytes, or a highly sensitive neuraminidase assay.

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20727998.001).
  • [ISSN] 1878-1705
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / Glycophorin; 0 / Sialoglycoproteins; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


26. Lesage J, Stanley J, Karoly WJ, Lichtenberg FW: Airborne methylene diphenyl diisocyanate (MDI) concentrations associated with the application of polyurethane spray foam in residential construction. J Occup Environ Hyg; 2007 Feb;4(2):145-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spray foam applicators and assistants may be exposed to airborne MDI concentrations above the OSHA permissible exposure limit.
  • At these concentrations, OSHA recommends appropriate respiratory protection during spray foam application to prevent airborne MDI exposures above established limits and to protect against exposure to dichlorofluoroethane (HCFC-141b).
  • After 45 min, airborne concentrations were below the limit of quantitation (LOQ) of 0.036-microg per sample.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Chlorofluorocarbons / analysis. Isocyanates / analysis. Occupational Exposure / analysis. Polyurethanes
  • [MeSH-minor] Canada. Chlorofluorocarbons, Ethane. Facility Design and Construction. Housing. Humans. Particle Size. Threshold Limit Values. United States

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. 4,4'-Methylenediphenyl Diisocyanate .
  • Hazardous Substances Data Bank. 1,1-DICHLORO-1-FLUOROETHANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249149.001).
  • [ISSN] 1545-9624
  • [Journal-full-title] Journal of occupational and environmental hygiene
  • [ISO-abbreviation] J Occup Environ Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Chlorofluorocarbons; 0 / Chlorofluorocarbons, Ethane; 0 / Isocyanates; 0 / Polyurethanes; 101-68-8 / 4,4'-diphenylmethane diisocyanate; 1717-00-6 / 1,1-dichloro-1-fluoroethane; 9009-54-5 / polyurethane foam
  •  go-up   go-down


27. Sabatini N, Di Giacomo V, Rapino M, Rana R, Garaci G, Cataldi A: JNK/p53 mediated cell death response in K562 exposed to etoposide-ionizing radiation combined treatment. J Cell Biochem; 2005 Jun 1;95(3):611-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since drug and ionizing radiation resistance is an impediment to successful chemotherapy against cancer, we wanted to check if etoposide/ionizing radiation combined treatment could have a synergic effect to improve cell death in K562, a well-known human erythroleukemia ionizing radiation resistant cell line.
  • Thus further investigation on these and other molecular mechanisms underlying the cell death response following etoposide and ionizing radiation exposure could be useful to overcome resistance mechanisms in tumor cells.
  • [MeSH-minor] Cell Death / drug effects. Cell Death / radiation effects. Humans. K562 Cells. Leukemia, Erythroblastic, Acute / therapy. MAP Kinase Kinase 4

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • [ErratumIn] J Cell Biochem. 2005 Sep 1;96(1):220. Giuseppe, Francesco [corrected to Garaci, G]
  • (PMID = 15832344.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 4; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


28. Constantinescu P, Wang B, Kovacevic K, Jalilian I, Bosman GJ, Wiley JS, Sluyter R: P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochim Biophys Acta; 2010 Sep;1798(9):1797-804
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells.
  • Extracellular ATP induces cation fluxes in and impairs the growth of murine erythroleukemia (MEL) cells in a manner characteristic of the purinergic P2X7 receptor, however the presence of P2X7 in these cells is unknown.
  • Finally, cytofluorometric measurements of Annexin-V binding and bio-maleimide staining demonstrated that ATP could induce rapid phosphatidylserine exposure and microparticle release in MEL cells respectively, both of which were impaired by A-438079.
  • [MeSH-major] Apoptosis. Leukemia, Erythroblastic, Acute / pathology. Receptors, Purinergic P2 / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20529664.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / P2rx7 protein, mouse; 0 / Phosphatidylserines; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X7; 8L70Q75FXE / Adenosine Triphosphate; EN464416SI / Ethidium
  •  go-up   go-down


29. Yang SH, Wu ZZ, Chien CM, Lo YH, Wu MJ, Chang LS, Lin SR: JNK and ERK mitogen-activated protein kinases mediate THDA-induced apoptosis in K562 cells. Cell Biol Toxicol; 2008 Aug;24(4):291-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2-(6-(2-thieanisyl)-3(Z)-hexen-1, 5-diynyl) aniline (THDA), an enediyne compound, was identified in our laboratory as a novel antineoplastic agent against human leukemia K562 cells.
  • In addition, the mitogen-activated protein family kinases, including c-Jun N-terminal kinase (JNK) and extracellular signal-regulated protein kinase (ERK) kinases, and the transcription factor c-Jun were all activated by phosphorylation after 6 h exposure to THDA.
  • [MeSH-major] Aniline Compounds / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Enediynes / pharmacology. Extracellular Signal-Regulated MAP Kinases / metabolism. JNK Mitogen-Activated Protein Kinases / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Signal Transduction / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17934787.001).
  • [ISSN] 0742-2091
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(6-(2-thieanisyl)-3-hexen-1,5-diynyl)aniline; 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / Enediynes; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-jun; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 0 / bcl-2-Associated X Protein; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


30. Nadali F, Pourfathollah AA, Alimoghaddam K, Nikougoftar M, Rostami S, Dizaji A, Azizi E, Zomorodipour A, Ghavamzadeh A: Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology; 2007 Oct;12(5):393-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Acute myeloblastic leukemia (AML) is the most common form of acute leukemia in adults.
  • One major problem in this disease is the emergence of leukemic blast cells that are resistant to anticancer drugs.
  • One cause of MDR is the expression of the MDR1 gene and its product, P-glycoprotein (Pgp).
  • MATERIALS AND METHODS: The Pgp expressing cell line was established from a parental K562 (Erythroleukemia) cell line with increasing concentrations of doxorubicin, and named KDI/20.
  • The effect of PS-ODN was assessed at the cellular level by flow cytometry (for Pgp detection), and Rhodamine 123 assay (for functional assessment of Pgp) at the molecular level by RT-PCR (for MDR1/mRNA detection) and MTT assay in order to assess the sensitivity of cell to doxorubicin.
  • Therefore, our data showed that antisense can reverse the MDR phenotype at the transcription level and the PEI vector is more efficient than cationic lipid.
  • [MeSH-major] Drug Resistance, Multiple / drug effects. Leukemia / drug therapy. Oligonucleotides, Antisense / pharmacology. P-Glycoprotein / drug effects. RNA, Messenger / drug effects

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852455.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Oligonucleotides; 0 / Oligonucleotides, Antisense; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / Thionucleotides; 80168379AG / Doxorubicin
  •  go-up   go-down


31. Tan PK, Wang J, Littler PL, Wong KK, Sweetnam TA, Keefe W, Nash NR, Reding EC, Piu F, Brann MR, Schiffer HH: Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer. Mol Pharmacol; 2007 Dec;72(6):1440-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 22 BRET assays have been established for nine RTKs derived from four subfamilies [erythroblastic leukemia viral (v-erb-b) oncogene homolog (ErbB), platelet-derived growth factor (PDGF), neurotrophic tyrosine kinase receptor (TRK), vascular endothelial growth factor (VEGF)] monitoring the interactions with five effectors (Grb2, p85, Stat5a, Shc46, PLCgamma1).
  • RTK BRET assays are highly sensitive for quantifying ligand-independent (constitutive), agonist-induced, or antagonist-inhibited RTK activity levels.


32. Selga E, Oleaga C, Ramírez S, de Almagro MC, Noé V, Ciudad CJ: Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med; 2009;1(9):83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Networking of differentially expressed genes in human cancer cells resistant to methotrexate.
  • These are especially useful to rationalize how external perturbations propagate through the expression of genes.
  • To address this issue in the case of drug resistance, we constructed biological association networks of genes differentially expressed in cell lines resistant to methotrexate (MTX).
  • METHODS: Seven cell lines representative of different types of cancer, including colon cancer (HT29 and Caco2), breast cancer (MCF-7 and MDA-MB-468), pancreatic cancer (MIA PaCa-2), erythroblastic leukemia (K562) and osteosarcoma (Saos-2), were used.
  • Genes deregulated in common between the different cancer cell lines served to generate biological association networks using the Pathway Architect software.
  • RESULTS: Dikkopf homolog-1 (DKK1) is a highly interconnected node in the network generated with genes in common between the two colon cancer cell lines, and functional validations of this target using small interfering RNAs (siRNAs) showed a chemosensitization toward MTX.
  • Members of the UDP-glucuronosyltransferase 1A (UGT1A) family formed a network of genes differentially expressed in the two breast cancer cell lines. siRNA treatment against UGT1A also showed an increase in MTX sensitivity.
  • Eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) was overexpressed among the pancreatic cancer, leukemia and osteosarcoma cell lines, and siRNA treatment against EEF1A1 produced a chemosensitization toward MTX.
  • CONCLUSIONS: Biological association networks identified DKK1, UGT1As and EEF1A1 as important gene nodes in MTX-resistance.
  • Treatments using siRNA technology against these three genes showed chemosensitization toward MTX.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(24):9328-32 [3540935.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):16-20 [6583326.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):646-53 [17245340.001]
  • [Cites] J Nutr Biochem. 2007 Aug;18(8):541-52 [17320366.001]
  • [Cites] BMC Bioinformatics. 2007;8:250 [17626636.001]
  • [Cites] Biochimie. 2007 Dec;89(12):1544-52 [17825975.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] J Clin Oncol. 1984 Jan;2(1):62-4 [6699659.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):6031-5 [8261418.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):984-7 [8640790.001]
  • [Cites] J Cell Sci. 1996 Nov;109 ( Pt 11):2705-14 [8937988.001]
  • [Cites] Drug Metab Dispos. 1997 Mar;25(3):367-70 [9172956.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(3):215-24 [9219504.001]
  • [Cites] Pharmacogenetics. 1997 Aug;7(4):255-69 [9295054.001]
  • [Cites] J Biol Chem. 1998 Jan 30;273(5):2526-31 [9446553.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1764-9 [9465091.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):847-54 [9466980.001]
  • [Cites] Jpn J Cancer Res. 1997 Dec;88(12):1211-7 [9473740.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8719-26 [9535849.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2695-700 [9703931.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):731-6 [9713282.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):587-92 [9773801.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30189-98 [9804775.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50 [10359783.001]
  • [Cites] Biochem Pharmacol. 2008 Jan 15;75(2):414-26 [17945194.001]
  • [Cites] Cancer Treat Rev. 2008 Oct;34(6):505-20 [18413281.001]
  • [Cites] BMC Med Genomics. 2008;1:35 [18694510.001]
  • [Cites] J Biol Chem. 1976 May 25;251(10):3063-74 [944697.001]
  • [Cites] Mol Pharmacol. 1999 Jul;56(1):68-76 [10385685.001]
  • [Cites] Mech Dev. 1999 Sep;87(1-2):45-56 [10495270.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):422-6 [10501917.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5938-46 [10606239.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1735-42 [10674022.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Br J Cancer. 2000 Oct;83(8):1047-54 [10993653.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):242-5 [11125103.001]
  • [Cites] Curr Biol. 2001 Jun 26;11(12):951-61 [11448771.001]
  • [Cites] J Comput Biol. 2001;8(6):557-69 [11747612.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):518-27 [11809704.001]
  • [Cites] FEBS Lett. 2002 Feb 20;513(1):135-40 [11911893.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):E172-3 [12105428.001]
  • [Cites] Cell Death Differ. 2002 Aug;9(8):856-61 [12107828.001]
  • [Cites] Trends Biotechnol. 2002 Nov;20(11):467-72 [12413821.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28067-78 [12740383.001]
  • [Cites] Pharmacogenomics J. 2003;3(3):136-58 [12815363.001]
  • [Cites] J Mol Med (Berl). 2003 Sep;81(9):536-48 [12898041.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8443-50 [14679008.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1098-103 [15592505.001]
  • [Cites] Nucleic Acids Res. 2005;33(3):864-72 [15701758.001]
  • [Cites] Pharmacol Ther. 2005 Apr;106(1):97-132 [15781124.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4295-304 [15958610.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1699-712 [16217747.001]
  • [Cites] Food Chem Toxicol. 2006 Aug;44(8):1251-60 [16545899.001]
  • [Cites] Oncogene. 2006 Mar 13;25(11):1659-72 [16550166.001]
  • [Cites] BMC Bioinformatics. 2006;7:373 [16901352.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):964-70 [17876334.001]
  • [Cites] BMC Cancer. 2007;7:182 [17894856.001]
  • [Cites] Biochemistry. 1976 Apr 6;15(7):1375-81 [1259943.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):333-6 [1383827.001]
  • [Cites] Semin Cancer Biol. 1991 Aug;2(4):245-55 [1912529.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3921-7 [2112982.001]
  • [Cites] Biochem Pharmacol. 1990 May 1;39(9):1459-65 [2334445.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Oct;86(19):7520-1 [2508089.001]
  • [Cites] J Biol Chem. 1989 Feb 25;264(6):3524-8 [2914962.001]
  • (PMID = 19732436.001).
  • [ISSN] 1756-994X
  • [Journal-full-title] Genome medicine
  • [ISO-abbreviation] Genome Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2768990
  •  go-up   go-down


33. Palusa SG, Golovkin M, Shin SB, Richardson DN, Reddy AS: Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis. New Phytol; 2007;174(3):537-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific, developmental, hormonal and stress regulation of expression of putative pectate lyase genes in Arabidopsis.
  • Pectate lyases catalyse the eliminative cleavage of de-esterified homogalacturonan in pectin, a major component of the primary cell walls in higher plants.
  • In the completed genome of Arabidopsis, there are 26 genes (AtPLLs) that encode pectate lyase-like proteins.
  • Interestingly, all PLL genes are expressed in flowers.
  • Analysis of expression of all PLL genes in seedlings treated with hormones, abiotic stresses and elicitors of defense responses revealed significant changes in the expression of some PLLs without affecting the other PLLs.
  • The stability of transcripts of PLLs varied considerably among different genes.
  • [MeSH-major] Arabidopsis / genetics. Arabidopsis Proteins / genetics. Gene Expression Regulation, Plant. Polysaccharide-Lyases / genetics

  • The Arabidopsis Information Resource. Linked Gene Data (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447910.001).
  • [ISSN] 0028-646X
  • [Journal-full-title] The New phytologist
  • [ISO-abbreviation] New Phytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabidopsis Proteins; 0 / Deoxyadenosines; 0 / RNA, Messenger; 73-03-0 / cordycepin; EC 4.2.2.- / Polysaccharide-Lyases; EC 4.2.2.2 / pectate lyase
  •  go-up   go-down


34. De Filippi R, Iaccarino G, Frigeri F, Di Francia R, Crisci S, Capobianco G, Arcamone M, Becchimanzi C, Amoroso B, De Chiara A, Corazzelli G, Pinto A: Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol; 2009 Nov;147(3):405-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681885.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


35. Xu R, Shi X, Zhang W, Xu Y, Tian Z, Lu X, Han X, Bao X: Cooperative structure-directing effect in the synthesis of aluminophosphate molecular sieves in ionic liquids. Phys Chem Chem Phys; 2010 Mar 14;12(10):2443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combining with the characterizations of the solid products by solid-state NMR, it is verified that different aggregates of organic amines with imidazolium cations, which is similar to self-assembled supramolecular analogues, could act as the structure-directing agents for selective tuning of the framework topologies such as AEL, AFI and LTA in the final solid products.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449358.001).
  • [ISSN] 1463-9084
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Ionic Liquids; 0 / Phosphates; F92V3S521O / aluminum phosphate
  •  go-up   go-down


36. Prokhorova TA, Rigbolt KT, Johansen PT, Henningsen J, Kratchmarova I, Kassem M, Blagoev B: Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating human embryonic stem cells. Mol Cell Proteomics; 2009 May;8(5):959-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 811 identified membrane proteins, six displayed significantly higher expression levels in the undifferentiated state compared with differentiating cells.
  • This group includes the established marker CD133/Prominin-1 as well as novel candidates for hESC surface markers: Glypican-4, Neuroligin-4, ErbB2, receptor-type tyrosine-protein phosphatase zeta (PTPRZ), and Glycoprotein M6B.
  • Our study also revealed 17 potential markers of hESC differentiation as their corresponding protein expression levels displayed a dramatic increase in differentiated embryonic stem cell populations.
  • [MeSH-minor] Animals. Biomarkers / metabolism. Cell Proliferation. Cells, Cultured. Culture Media, Conditioned. Gene Expression Regulation, Developmental. Humans. Mice. Phosphoproteins / analysis. Pluripotent Stem Cells / cytology. Proteomics. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods. 2006 Nov;40(3):243-50 [17071406.001]
  • [Cites] EMBO Rep. 2006 Sep;7(9):874-9 [16953200.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] Cloning Stem Cells. 2006 Winter;8(4):319-34 [17196096.001]
  • [Cites] Dev Biol. 2007 Apr 1;304(1):182-93 [17223098.001]
  • [Cites] Nat Protoc. 2006;1(6):2856-60 [17406544.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):961-73 [17204602.001]
  • [Cites] Nat Biotechnol. 2007 May;25(5):566-8 [17450129.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5727-36 [17575139.001]
  • [Cites] Nat Biotechnol. 2007 Jul;25(7):803-16 [17572666.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W429-32 [17483518.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1888-903 [17495109.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):677-8 [17762871.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2007 Aug;14(4):277-82 [17940452.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4111-9 [17761519.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] J Pathol. 2008 Jan;214(1):3-9 [18067118.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1917-20 [18029452.001]
  • [Cites] Exp Mol Med. 2007 Dec 31;39(6):690-5 [18160839.001]
  • [Cites] Gene Ther. 2008 Jan;15(2):74-81 [17989701.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):101-6 [18059259.001]
  • [Cites] Nat Biotechnol. 2008 Feb;26(2):164-7 [18259167.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2451-6 [18268350.001]
  • [Cites] Cell. 2008 Feb 22;132(4):567-82 [18295576.001]
  • [Cites] Mol Cell Proteomics. 2008 Apr;7(4):672-83 [18045802.001]
  • [Cites] Mol Cell Proteomics. 2008 Apr;7(4):750-67 [18304949.001]
  • [Cites] Cell. 2008 Apr 18;133(2):250-64 [18423197.001]
  • [Cites] J Proteome Res. 2008 Jul;7(7):2936-51 [18489135.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1587-97 [18487603.001]
  • [Cites] Stem Cells Dev. 2009 Jan-Feb;18(1):47-54 [18393673.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Dev Dyn. 2000 Nov;219(3):353-67 [11066092.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):971-4 [11581665.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Neurosci Res. 2003 Feb;45(2):219-24 [12573468.001]
  • [Cites] Anal Chem. 2003 Feb 1;75(3):663-70 [12585499.001]
  • [Cites] Nat Biotechnol. 2003 Mar;21(3):315-8 [12577067.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):173-81 [12716131.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5813-8 [12724530.001]
  • [Cites] Recent Prog Horm Res. 2004;59:1-12 [14749494.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1353-6 [14999088.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):15805-13 [14739304.001]
  • [Cites] Nat Biotechnol. 2004 Sep;22(9):1139-45 [15314609.001]
  • [Cites] Dev Biol. 2004 Nov 15;275(2):269-86 [15501218.001]
  • [Cites] Semin Cancer Biol. 1993 Feb;4(1):19-26 [8095411.001]
  • [Cites] Genomics. 1996 May 1;33(3):532-6 [8661015.001]
  • [Cites] Proteomics. 2005 Apr;5(5):1346-61 [15742316.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):617-21 [15834404.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):791-804 [15917475.001]
  • [Cites] Science. 2005 Jun 3;308(5727):1472-7 [15933201.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):699-708 [15940242.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Blood Rev. 2005 Nov;19(6):321-31 [16275420.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):568-74 [16282444.001]
  • [Cites] Mol Cell Proteomics. 2006 Jul;5(7):1261-73 [16600995.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Expert Rev Proteomics. 2006 Aug;3(4):427-37 [16901201.001]
  • [Cites] Cell. 2006 Aug 25;126(4):663-76 [16904174.001]
  • [Cites] Reproduction. 2006 Nov;132(5):691-8 [17071770.001]
  • (PMID = 19151416.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Biomarkers; 0 / Culture Media, Conditioned; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Proteome; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2689770
  •  go-up   go-down


37. Jost PJ, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood; 2007 Apr 1;109(7):2700-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma.
  • Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase.
  • This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL).
  • [MeSH-minor] Hodgkin Disease / physiopathology. Humans. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Lymphocytes / physiology. Lymphoma, B-Cell / physiopathology. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / physiopathology. Lymphoma, Large B-Cell, Diffuse / physiopathology. Models, Biological. Oncogene Proteins, Viral / physiology. Prognosis. Signal Transduction / physiology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119127.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Oncogene Proteins, Viral
  • [Number-of-references] 96
  •  go-up   go-down


38. Küçükkaya B, Oztürk G, Yalçintepe L: Nitric oxide levels during erythroid differentiation in K562 cell line. Indian J Biochem Biophys; 2006 Aug;43(4):251-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide levels during erythroid differentiation in K562 cell line.
  • This study was designed to investigate the possible role of NO during erythroid differentiation in K562 erythroleukemia cells.
  • The chronic myelogenous leukemia (K562) cell line can be triggered in culture to differentiate along the erythrocytic pathway, in response to a variety of stimulatory agents.
  • We investigated NOx (nitrate+nitrite) levels in uninduced (control) and hemin-induced K562 cell lysates during erythroid differentiation.
  • Our results showed that NO levels decreased significantly on fourth and sixth day both in hemin-induced and control cells; the decrease was, however, more in hemin-induced group than in control group.

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17133771.001).
  • [ISSN] 0301-1208
  • [Journal-full-title] Indian journal of biochemistry & biophysics
  • [ISO-abbreviation] Indian J. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Nitrates; 0 / Nitrites; 31C4KY9ESH / Nitric Oxide; 743LRP9S7N / Hemin
  •  go-up   go-down


39. Yamaguchi T, Koga T, Katsuki S: Water proton spin-lattice relaxation time during the apoptotic process in ultraviolet-irradiated murine erythroleukemia cells. J Physiol Sci; 2009 Mar;59(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Water proton spin-lattice relaxation time during the apoptotic process in ultraviolet-irradiated murine erythroleukemia cells.
  • Thus, we examined the (1)H spin-lattice relaxation time (T1) of intracellular water during apoptosis in murine erythroleukemia (MEL) cells.
  • [MeSH-major] Apoptosis / radiation effects. Leukemia, Erythroblastic, Acute / pathology. Leukemia, Erythroblastic, Acute / radiotherapy. Osmosis / radiation effects. Protons. Water
  • [MeSH-minor] Animals. Caspases / metabolism. Cell Line, Tumor. Cell Membrane / radiation effects. Cell Membrane / ultrastructure. Cell Size / radiation effects. DNA Fragmentation / radiation effects. Disease Models, Animal. Mice. Ultraviolet Rays

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2004 Jul 1;297(1):212-23 [15194437.001]
  • [Cites] J Biochem. 2001 Jul;130(1):1-8 [11432772.001]
  • [Cites] Jpn J Physiol. 2001 Apr;51(2):193-9 [11405912.001]
  • [Cites] Cell. 2000 Jul 7;102(1):1-4 [10929706.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19346-52 [11919192.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9487-92 [10900263.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21953-62 [10419518.001]
  • [Cites] Exp Cell Res. 1999 Oct 10;252(1):63-74 [10502400.001]
  • [Cites] Cancer Res. 1975 May;35(5):1164-7 [1120306.001]
  • [Cites] Biophys J. 2003 Jan;84(1):558-63 [12524308.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • (PMID = 19340553.001).
  • [ISSN] 1880-6562
  • [Journal-full-title] The journal of physiological sciences : JPS
  • [ISO-abbreviation] J Physiol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Protons; 059QF0KO0R / Water; EC 3.4.22.- / Caspases
  •  go-up   go-down


40. Towata T, Komizu Y, Suzu S, Ueoka R, Okada S: Highly selective fusion and accumulation of hybrid liposomes into primary effusion lymphoma cells along with induction of apoptosis. Biochem Biophys Res Commun; 2010 Mar 12;393(3):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an aggressive neoplasm caused by human herpes virus-8 infection, and is generally resistant to chemotherapy.
  • Hybrid liposomes, composed of dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (21) dodecyl ether (C12(EO)21) (HL-21), were rapidly accumulated in the membrane of PEL cells.
  • HL-21 also increased membrane fluidity of PEL cells, and induced caspase-3 activation along with cell death.
  • These results suggest that HL-21 should be an effective and attractive regent for PEL treatment.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20138834.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols; U86ZGC74V5 / Dimyristoylphosphatidylcholine
  •  go-up   go-down


41. Simonelli C, Tedeschi R, Gloghini A, Bortolin MT, Spina M, Bidoli E, Cinelli R, De Paoli P, Carbone A, Tirelli U: Characterization of immunologic and virological parameters in HIV-infected patients with primary effusion lymphoma during antiblastic therapy and highly active antiretroviral therapy. Clin Infect Dis; 2005 Apr 1;40(7):1022-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary effusion lymphoma (PEL) represents a peculiar lymphoma infected with human herpesvirus 8 (HHV-8) and occurs predominantly in human immunodeficiency virus (HIV)-infected patients.
  • The aim of the present study was to evaluate the immunologic and virological parameters, including HHV-8 viremia, of 5 HIV-infected patients with PEL whose disease was diagnosed and treated at our institute.
  • Biological parameters, such as latent and lytic HHV-8 antigen levels, plasma HHV-8 load, Epstein-Barr virus plasma DNA load, HIV-1 load, and CD4 cell count, were assessed before treatment, during therapy, and at follow-up.
  • RESULTS: Four patients were treated with chemotherapy and highly active antiretroviral therapy (HAART), and 1 was treated with HAART alone; 3 of 5 patients reached complete remission.
  • HHV-8 levels decreased after therapy in 4 patients.
  • CONCLUSIONS: Our analysis demonstrates that HHV-8 can be detected in the plasma at the onset of PEL; its prognostic role needs to be explored.
  • CD4 cell count seems to be the most important indicator of progression of PEL.
  • [MeSH-minor] Adult. Anti-HIV Agents. CD4 Lymphocyte Count. Disease Progression. Female. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Humans. Male. Viral Load. Viral Proteins / metabolism. Viremia


42. Mardini L, Gasiorek J, Derjuga A, Carrière L, Schranzhofer M, Paw BH, Ponka P, Blank V: Antagonistic roles of the ERK and p38 MAPK signalling pathways in globin expression, haem biosynthesis and iron uptake. Biochem J; 2010 Nov 15;432(1):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Late-stage erythroid cells synthesize large quantities of haemoglobin, a process requiring the co-ordinated regulation of globin and haem synthesis as well as iron uptake.
  • In the present study, we investigated the role of the ERK (extracellular-signal-regulated kinase) and p38 MAPK (mitogen-activated protein kinase) signalling pathways in MEL (mouse erythroleukaemia) cell differentiation.
  • We found that treatment of HMBA (hexamethylene bisacetamide)-induced MEL cells with the ERK pathway inhibitor UO126 results in an increase in intracellular haem and haemoglobin levels.
  • The transcript levels of the genes coding for β(major)-globin, the haem biosynthesis enzyme 5-aminolevulinate synthase 2 and the mitochondrial iron transporter mitoferrin 1 are up-regulated.
  • Reporter assays showed that globin promoter and HS2 enhancer-mediated transcription was under the control of MAPKs, as inhibition of the ERK and p38 MAPK pathways led to increased and decreased gene activity respectively.
  • Our present results suggest that the ERK1/2 and p38α/β MAPKs play antagonistic roles in HMBA-induced globin gene expression and erythroid differentiation.
  • These results provide a novel link between MAPK signalling and the regulation of haem biosynthesis and iron uptake in erythroid cells.

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738258.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL032262; United States / NIDDK NIH HHS / DK / R01 DK070838; Canada / Canadian Institutes of Health Research / / MOP-79361
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; 0 / Acetamides; 0 / Antineoplastic Agents; 0 / Butadienes; 0 / Enzyme Inhibitors; 0 / Hemoglobins; 0 / Imidazoles; 0 / Nitriles; 0 / Pyridines; 0 / U 0126; 42VZT0U6YR / Heme; 9004-22-2 / Globins; E1UOL152H7 / Iron; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; LA133J59VU / hexamethylene bisacetamide
  •  go-up   go-down


43. Chen D, Sandford G, Nicholas J: Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J Virol; 2009 Jan;83(2):722-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While vIL-6 is generally considered to be a lytic gene, several reports have noted its low-level expression in latently infected primary effusion lymphoma (PEL) cultures, in the absence of other lytic gene expression.
  • Knockdown of vIL-6 expression in PEL cells led to markedly reduced cell growth in normal culture, independently of extracellular cytokines.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Med. 2003;76:367-82 [12526175.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):449-60 [14611646.001]
  • [Cites] Blood. 1989 Sep;74(4):1360-7 [2788466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 [1693429.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):22084-91 [8408066.001]
  • [Cites] Nat Med. 1997 Mar;3(3):287-92 [9055855.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1858-63 [9490667.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Infect Dis. 1999 Sep;180(3):824-8 [10438372.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] J Virol. 2006 Sep;80(17):8510-20 [16912301.001]
  • [Cites] J Virol. 2006 Oct;80(19):9811-21 [16973585.001]
  • [Cites] J Virol. 2006 Nov;80(21):10874-8 [16956953.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):712-20 [18347156.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3604-12 [10848977.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):18810-7 [10764798.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):332-5 [10861641.001]
  • [Cites] Hum Pathol. 2001 Jan;32(1):95-100 [11172301.001]
  • [Cites] J Virol. 2001 Apr;75(7):3325-34 [11238858.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] J Virol. 2002 Apr;76(7):3421-39 [11884567.001]
  • [Cites] J Virol. 2002 Jun;76(11):5627-36 [11991991.001]
  • [Cites] J Mol Biol. 2004 Jan 9;335(2):641-54 [14672670.001]
  • (PMID = 18987143.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076445; United States / NCI NIH HHS / CA / R01-CA76445
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL6R protein, human; 0 / Interleukin-6; 0 / Receptors, Interleukin-6; 0 / Viral Proteins; 0 / interleukin-6, RRV-HHV-8; 133483-10-0 / Cytokine Receptor gp130
  • [Other-IDs] NLM/ PMC2612405
  •  go-up   go-down


44. Tsai YH, Wu MF, Wu YH, Chang SJ, Lin SF, Sharp TV, Wang HW: The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. J Virol; 2009 Jan;83(2):622-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion.
  • The KSHV open reading frame K15 is a KSHV-specific gene encoding a transmembrane protein.
  • The two K15 alleles resemble the latent membrane protein 2A (LMP2A) gene of Epstein-Barr virus (EBV) in their genomic locations and protein topology.
  • K15 therefore appears to be a hybrid of a distant evolutionary relative of EBV LMP1 and LMP2A.
  • In this study, we show that K15M is latently expressed in KSHV-positive PEL cells and knockdown of K15M in PEL cells reduces cell motility.
  • [MeSH-minor] Cell Line, Tumor. Cell Migration Assays. Gene Knockdown Techniques. Humans. Intracellular Membranes / chemistry. Lysosomes / chemistry. NF-kappa B / biosynthesis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Jan;74(1):436-46 [10590133.001]
  • [Cites] J Virol. 2007 Jan;81(1):42-58 [17050609.001]
  • [Cites] Oncogene. 2000 Apr 6;19(15):1915-23 [10773881.001]
  • [Cites] Virology. 2000 Dec 5;278(1):60-74 [11112482.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • [Cites] J Dermatol. 2000 Nov;27(11):740-4 [11138542.001]
  • [Cites] Cancer Treat Res. 2001;104:89-126 [11191137.001]
  • [Cites] J Virol. 2002 Jan;76(2):802-16 [11752170.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2602-15 [12032073.001]
  • [Cites] Int Rev Cytol. 2002;216:233-89 [12049209.001]
  • [Cites] Curr Opin Pulm Med. 2002 Jul;8(4):317-22 [12055396.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jun;1(6):415-26 [12119743.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] J Virol. 2002 Sep;76(18):9556-61 [12186939.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):256-62 [12517806.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2):143-53 [12704591.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):797-812 [12808115.001]
  • [Cites] J Virol. 2003 Sep;77(17):9346-58 [12915550.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4145-50 [14519638.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2774-81 [15087393.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Nat Rev Microbiol. 2004 Aug;2(8):656-68 [15263900.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):425-35 [15314073.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3621-6 [9520415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51 [10200299.001]
  • [Cites] J Virol. 1999 Aug;73(8):6646-60 [10400762.001]
  • [Cites] J Virol. 1999 Aug;73(8):6953-63 [10400794.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):2993-5 [15833821.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Dec;37(12):2457-65 [16188485.001]
  • [Cites] J Virol. 2005 Dec;79(24):15430-42 [16306614.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):886-97 [16239905.001]
  • [Cites] J Gen Virol. 2007 Jun;88(Pt 6):1698-707 [17485529.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]
  • [Cites] J Virol. 2007 Jul;81(13):7001-10 [17442715.001]
  • [Cites] Circ Res. 2007 Jul 6;101(1):59-68 [17540974.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] Trends Pharmacol Sci. 2008 Jan;29(1):12-5 [18068232.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] Oncology. 2007;72(5-6):397-402 [18196926.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Chest. 2000 Feb;117(2):410-4 [10669683.001]
  • (PMID = 18971265.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / K15 protein, Human herpesvirus 8; 0 / MIRN21 microRNA, human; 0 / MIRN31 microRNA, human; 0 / MicroRNAs; 0 / NF-kappa B; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2612383
  •  go-up   go-down


45. Dykxhoorn DM, Schlehuber LD, London IM, Lieberman J: Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci U S A; 2006 Apr 11;103(15):5953-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A single nucleotide polymorphism (SNP) in the sickle beta-globin gene (beta(S)) leads to sickle cell anemia.
  • RNA interference (RNAi) uses small interfering (si)RNAs for sequence-specific gene silencing.
  • A beta(S) siRNA with position 10 of the guide strand designed to align with the targeted beta(S) SNP specifically silences beta(S) gene expression without affecting the expression of the gamma-globin or normal beta-globin (beta(A)) genes.
  • Specific beta(S) silencing was demonstrated by using a luciferase reporter and full-length beta(S) cDNA transfected into HeLa cells and mouse erythroleukemia cells, where it was expressed in the context of the endogenous beta-globin gene promoter and the locus control region enhancers.
  • When this strategy was used to target beta(E), silencing was not limited to the mutant gene but also targeted the normal beta(A) gene. siRNAs, mismatched with their target at position 10, guided mRNA cleavage in all cases except when two bulky purines were aligned.
  • The specific silencing of the beta(S)-globin gene, as compared with beta(E), as well as studies of silencing SNP mutants in other diseases, indicates that siRNAs developed to target a disease-causing SNP will be specific if the mutant residue is a pyrimidine and the normal residue is a purine.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2005;56:401-23 [15660519.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):663-6 [15800628.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):666-70 [15800629.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):709-17 [15908939.001]
  • [Cites] Blood. 2005 Aug 1;106(3):818-26 [15831707.001]
  • [Cites] Nat Biotechnol. 2006 Jan;24(1):89-94 [16378095.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6877-88 [11726523.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2368-71 [11743206.001]
  • [Cites] Nucleic Acids Res. 2002 Apr 15;30(8):1757-66 [11937629.001]
  • [Cites] Nat Med. 2002 Jul;8(7):681-6 [12042777.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):435-8 [12087358.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):243-7 [12242156.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7195-200 [12782788.001]
  • [Cites] RNA. 2003 Sep;9(9):1034-48 [12923253.001]
  • [Cites] Aging Cell. 2003 Aug;2(4):209-17 [12934714.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44312-9 [12952966.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):326-30 [14758366.001]
  • [Cites] Lancet. 2004 Oct 9-15;364(9442):1343-60 [15474138.001]
  • [Cites] Blood. 1987 Jan;69(1):109-16 [2431728.001]
  • [Cites] Ann N Y Acad Sci. 1998 Jun 30;850:334-43 [9668555.001]
  • [Cites] Nucleic Acids Res. 2005;33(5):1671-7 [15781493.001]
  • (PMID = 16585504.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5 T32 HL007556-19; United States / NHLBI NIH HHS / HL / P01 HL 055435-11; United States / NIAID NIH HHS / AI / U19 AI056900; United States / NIAID NIH HHS / AI / AI056900; United States / NHLBI NIH HHS / HL / P01 HL055435; United States / NHLBI NIH HHS / HL / T32 HL007556
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-22-2 / Globins; EC 1.13.12.5 / Luciferases, Renilla
  • [Other-IDs] NLM/ PMC1458679
  •  go-up   go-down


46. Di Donato A, Di Giampaolo L, Reale M, Dadorante V, Alparone F, Stocchi M, Fattorini E, Di Gioacchino M, Magrini A, Boscolo P: Effect of occupational stress and anxiety on natural killer lymphocyte activity of men and women employed in a university. Int J Immunopathol Pharmacol; 2006 Oct-Dec;19(4 Suppl):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of occupational stress and anxiety on natural killer lymphocyte activity of men and women employed in a university.
  • The aim of this study is the immune response of the staff of a university and a museum (referent group).
  • Blood samples were collected for determining NK cytotoxic activity vs human erythroleukaemia cells and the lymphocyte subsets CD45+, CD45+-CD3+, CD45+-CD3+-CD4+, CD45+-CD3+-CD8+, CD45+-CD3-CD8+, CD3+-CD16+-56+ and CD3+-CD19+.
  • Group F of men showed higher levels of occupational stress and both STAI I and II than groups E and G.
  • The scores of STAI I and II were negatively correlated with the cytotoxic activity expressed per ml of blood and/or total lymphocytes. and/or NK CD45+-CD16+-CD56+ cells.
  • [MeSH-minor] Adult. Female. Humans. Lymphocyte Subsets. Male. Middle Aged. Universities


47. Kettle R, Simmons J, Schindler F, Jones P, Dicker T, Dubois G, Giddings J, Van Heeke G, Jones CE: Regulation of neuregulin 1beta1-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol; 2010 Apr;42(4):472-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mucins, MUC5AC and MUC5B, contribute to the viscoelastic properties of mucus, and are found at elevated levels in the airways of individuals with chronic respiratory diseases.
  • The T helper type 2 cell cytokine, IL-13, is known to regulate MUC5AC expression in goblet cells of the airways, although much less is known about the regulation of MUC5B expression.
  • NRG1beta1-induced expression of MU5AC and MUC5B was shown to involve v-erb-b2 erythroblastic leukemia viral oncogene homolog (ErbB) and ErbB3 receptors, but not ErbB4 receptors.
  • [MeSH-major] Gene Expression Regulation. Goblet Cells / metabolism. Mucin 5AC / biosynthesis. Mucin-5B / biosynthesis. Neuregulin-1 / metabolism
  • [MeSH-minor] Animals. Cell Line. Cells, Cultured. Chronic Disease. Humans. Interleukin-13 / metabolism. Mice. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation / drug effects. Protein Kinase Inhibitors / pharmacology. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / metabolism. Receptor, ErbB-4. Respiration Disorders / metabolism. Th2 Cells / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556605.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-13; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / Mucin 5AC; 0 / Mucin-5B; 0 / NRG1 protein, human; 0 / Neuregulin-1; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Erbb4 protein, mouse; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


48. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB: Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol; 2008 Jan 15;75(2):405-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (EC1.1.1.88) inhibitors (statins) reduce cholesterol synthesis and prevent cardiovascular disease; they can also inhibit prenylation of Ras and Rho proteins, and have anti-neoplastic effects.
  • We found that the HMG-CoA reductase inhibitor lovastatin markedly induced the expression of RhoA, B, and C in human erythroleukemia (HEL) cells.

  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):111-26 [11149925.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31001-8 [10896672.001]
  • [Cites] Circulation. 2002 Feb 26;105(8):962-7 [11864926.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10678-82 [11788600.001]
  • [Cites] Circulation. 2002 Apr 16;105(15):1756-9 [11956113.001]
  • [Cites] Leukemia. 2002 Apr;16(4):508-19 [11960327.001]
  • [Cites] Circ Res. 2002 Jul 26;91(2):173-9 [12142351.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):363-73 [12193475.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):37382-93 [12119292.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2807-18 [12429740.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):133-42 [12635176.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3852-9 [12933658.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6597-608 [12944485.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1173-8 [12964001.001]
  • [Cites] Cardiovasc Res. 2004 Mar 1;61(4):745-55 [14985071.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):541-7 [15314078.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1604-7 [6257680.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3628-32 [1673788.001]
  • [Cites] Oncogene. 1991 Apr;6(4):515-22 [1903193.001]
  • [Cites] J Biol Chem. 1992 Oct 5;267(28):20033-8 [1400319.001]
  • [Cites] Science. 1993 Jan 29;259(5095):683-6 [8430318.001]
  • [Cites] EMBO J. 1993 May;12(5):1915-21 [8491184.001]
  • [Cites] J Biol Chem. 1993 Dec 5;268(34):25542-6 [8244990.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):26802-6 [7592920.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30366-74 [8939998.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):15591-4 [9188444.001]
  • [Cites] FEBS Lett. 1998 Jan 30;422(2):269-73 [9490022.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):483-91 [9816194.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):578-85 [9927417.001]
  • [Cites] Leuk Res. 2005 May;29(5):527-33 [15755505.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10182-8 [15640525.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:89-118 [15822172.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):405-12 [15864282.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19243-9 [15713677.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6054-62 [16024605.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):1-9 [16083425.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):34202-9 [16085653.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):16951-61 [16632465.001]
  • [Cites] Biochemistry. 2001 Sep 4;40(35):10542-9 [11523996.001]
  • (PMID = 17920041.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR051300-07; United States / NIAMS NIH HHS / AR / AR051300-07; United States / NIAMS NIH HHS / AR / AR051300-09; United States / NIAMS NIH HHS / AR / R01-AR051300; United States / NIAMS NIH HHS / AR / AR051300-08; United States / NHLBI NIH HHS / HL / 5T32-HL07261; United States / NIAMS NIH HHS / AR / R01 AR051300-09; United States / NHLBI NIH HHS / HL / T32 HL007261; United States / NIAMS NIH HHS / AR / R01 AR051300; United States / NIAMS NIH HHS / AR / R01 AR051300-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARHGDIA protein, human; 0 / Guanine Nucleotide Dissociation Inhibitors; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / RHOC protein, human; 0 / rho Guanine Nucleotide Dissociation Inhibitor alpha; 0 / rho-Specific Guanine Nucleotide Dissociation Inhibitors; 124671-05-2 / RHOA protein, human; 86-01-1 / Guanosine Triphosphate; 9LHU78OQFD / Lovastatin; EC 3.6.5.2 / rho GTP-Binding Proteins; EC 3.6.5.2 / rhoA GTP-Binding Protein; EC 3.6.5.2 / rhoB GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS37750; NLM/ PMC2228324
  •  go-up   go-down


49. Einarsdóttir K, Rosenberg LU, Humphreys K, Bonnard C, Palmgren J, Li Y, Li Y, Chia KS, Liu ET, Hall P, Liu J, Wedrén S: Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res; 2006;8(6):R67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study.
  • BACKGROUND: Mutations in the ataxia-telangiectasia mutated (ATM) and checkpoint kinase 2 (CHEK2) genes and amplification of the v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) gene have been suggested to have an important role in breast cancer aetiology.
  • However, whether common variation in these genes has a role in the development of breast cancer or breast cancer survival in humans is still not clear.
  • METHODS: We performed a comprehensive haplotype analysis of the ATM, CHEK2 and ERBB2 genes in a Swedish population-based study, which included 1,579 breast cancer cases and 1,516 controls.
  • We selected seven haplotype-tagging SNPs (tagSNPs) in the ATM gene, six tagSNPs in the CHEK2 gene and seven tagSNPs in the ERBB2 gene that predicted both haplotypic and single locus variations in the respective genes with R2 values > or = 0.8.
  • RESULTS: We found no association between any genetic variation in the ATM, CHEK2 or ERBB2 genes and breast cancer survival or the risk of developing tumours with certain characteristics.
  • CONCLUSION: Our results indicate that common variants in the ATM, CHEK2 or ERBB2 genes are not involved in modifying breast cancer survival or the risk of tumour-characteristic-defined breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Apr;21(4):359-60 [10192382.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):339-44 [10209946.001]
  • [Cites] N Engl J Med. 1991 Dec 26;325(26):1831-6 [1961222.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):221-36 [15557796.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):575-80 [15472904.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R204-9 [15743501.001]
  • [Cites] Breast Cancer Res Treat. 2005 Feb;89(3):309-12 [15754131.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):821-5 [15824150.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • [Cites] Am J Hum Genet. 2002 Aug;71(2):432-8 [12094328.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):89-90 [12205473.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5743-8 [12384533.001]
  • [Cites] Am J Hum Genet. 2002 Nov;71(5):1242-7 [12452179.001]
  • [Cites] Nat Genet. 2003 May;34(1):23-4; author reply 25 [12721549.001]
  • [Cites] Hum Hered. 2003;55(1):27-36 [12890923.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):733-8 [12917204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):809-12 [12917215.001]
  • [Cites] Am J Hum Genet. 2003 Sep;73(3):551-65 [12900796.001]
  • [Cites] Pharmacogenet Genomics. 2005 Jul;15(7):447-50 [15970791.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4775-8 [16000574.001]
  • [Cites] Eur J Hum Genet. 2006 Apr;14(4):426-37 [16479260.001]
  • [Cites] Ann Hum Genet. 2006 Mar;70(Pt 2):254-61 [16626335.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1537-43 [16622469.001]
  • [Cites] Hum Mutat. 2006 Jun;27(6):538-44 [16652348.001]
  • [Cites] PLoS Med. 2006 Jun;3(6):e168 [16671833.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):873-5 [16832357.001]
  • [Cites] Nat Rev Genet. 2006 Oct;7(10):812-20 [16983377.001]
  • [Cites] Genet Test. 1997-1998;1(3):165-70 [10464642.001]
  • [Cites] Science. 1985 Sep 6;229(4717):974-6 [2992089.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):226-30 [3945311.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1301-8 [7992835.001]
  • [Cites] Acta Oncol. 1995;34(2):145-52 [7718250.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1749-53 [7792600.001]
  • [Cites] Science. 1999 Nov 5;286(5442):1162-6 [10550055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14973-7 [10611322.001]
  • [Cites] Science. 1999 Dec 24;286(5449):2528-31 [10617473.001]
  • [Cites] Genes Dev. 2000 Feb 1;14(3):289-300 [10673501.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):201-4 [10724175.001]
  • [Cites] Cancer Causes Control. 2000 Jul;11(6):523-31 [10880034.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94 [10973490.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 17;93(2):121-7 [11208881.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Int J Cancer. 2001 Jul 20;95(4):205-8 [11400111.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):1-14 [11410837.001]
  • [Cites] JAMA. 2001 Jun 20;285(23):2975-7 [11410091.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):479-87 [11505391.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7608-15 [11606401.001]
  • [Cites] Stat Med. 2002 Jan 15;21(1):35-50 [11782049.001]
  • [Cites] Am J Epidemiol. 2002 Jan 15;155(2):176-84 [11790682.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30 [11805335.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):205-15 [11830610.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):76-83 [11857015.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3052-7 [12036913.001]
  • [Cites] Genome Res. 2002 Jun;12(6):969-75 [12045150.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):115-20 [12935922.001]
  • [Cites] Hum Hered. 2003;56(1-3):18-31 [14614235.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):840-3 [14871810.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1345-51 [15042666.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R416-22 [15217510.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5973-81 [15342376.001]
  • [Cites] J Med Genet. 2004 Oct;41(10):731-5 [15466005.001]
  • [Cites] Nature. 1984 Dec 6-12;312(5994):513-6 [6095109.001]
  • [Cites] Science. 1995 Jul 14;269(5221):230-4 [7618084.001]
  • [Cites] Nature. 1995 Nov 23;378(6555):394-8 [7477377.001]
  • [Cites] Nat Genet. 1997 Mar;15(3):307-10 [9054948.001]
  • [Cites] Am J Hum Genet. 1998 Feb;62(2):334-45 [9463314.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1376-9 [9537233.001]
  • [Cites] Cancer Causes Control. 1998 May;9(3):259-67 [9684706.001]
  • [Cites] Nature. 1998 Oct 1;395(6701):507-10 [9774107.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):791-808 [9797688.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):231-6 [9935204.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1347-55 [10096569.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1304-7 [10098776.001]
  • (PMID = 17132159.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104021; United States / NCI NIH HHS / CA / R01 CA 104021
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1797028
  •  go-up   go-down


50. Ratel D, Ravanat JL, Charles MP, Platet N, Breuillaud L, Lunardi J, Berger F, Wion D: Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase. FEBS Lett; 2006 May 29;580(13):3179-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undetectable levels of N6-methyl adenine in mouse DNA: Cloning and analysis of PRED28, a gene coding for a putative mammalian DNA adenine methyltransferase.
  • Three methylated bases, 5-methylcytosine, N4-methylcytosine and N6-methyladenine (m6A), can be found in DNA.
  • To reinvestigate the presence of m6A in mammalian DNA, we used a highly sensitive method capable of detecting one N6-methyldeoxyadenosine per million nucleosides.
  • Our results suggest that the total mouse genome contains, if any, less than 10(3) m6A.

  • HAL archives ouvertes. Full text from .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684535.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 5142-22-3 / 1-methyladenine; EC 2.1.1.72 / PRED28 protein, mouse; EC 2.1.1.72 / Site-Specific DNA-Methyltransferase (Adenine-Specific); JAC85A2161 / Adenine
  •  go-up   go-down


51. Brimo F, Popradi G, Michel RP, Auger M: Primary effusion lymphoma involving three body cavities. Cytojournal; 2009;6:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a human herpes virus-8 (HHV8)-associated large-cell non-Hodgkin lymphoma localized in body cavities and presenting as pleural, peritoneal, or pericardial lymphomatous effusions.
  • We describe herein a case of PEL affecting three body cavity sites in an immunocompetent patient.
  • An examination of the fluid by cytology showed large atypical lymphocytes with abundant basophilic cytoplasm, either central or eccentric nuclei having irregular outlines, and multiple prominent nucleoli.
  • A diagnosis of PEL was rendered.
  • Despite chemotherapy and valganciclovir, the disease progressed to involve the pleural and pericardial cavities and the patient died 5 months following the initial diagnosis.
  • Although PEL is a B-cell lymphoma, it is usually of null phenotype by immunohistochemistry, and can rarely aberrantly express T-cell markers, as seen in the current case.
  • The key to the diagnosis of PEL rests on identifying HHV8 in the neoplastic cells.
  • Therefore, restricting the term of PEL only to those cases that are HHV8 positive is important in order to differentiate PEL from other lymphomas that can present as serous effusions and that carry, in general, a more favorable prognosis than PEL.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Eur J Haematol. 2003 Jul;71(1):62-7 [12801300.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):493-9 [9537479.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Eur Respir J. 1999 Nov;14(5):1231-4 [10596717.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):944-50 [12218212.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):456-60 [14990970.001]
  • [Cites] Acta Cytol. 2004 May-Jun;48(3):425-30 [15192964.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1567-9 [16847420.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] APMIS. 2009 Mar;117(3):222-9 [19245595.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Diagn Cytopathol. 1997 Aug;17(2):134-7 [9258621.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1528-37 [9850179.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):498-502 [10349390.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Am J Hematol. 2000 Dec;65(4):310-4 [11074561.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1112-5 [11167749.001]
  • [Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):330-4 [15023036.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1022-7 [15824995.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Acta Haematol. 2007;117(3):132-44 [17135726.001]
  • [Cites] Cancer. 2008 Aug 25;114(4):225-7 [18473348.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1236-7 [18525275.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):101-4 [9013840.001]
  • (PMID = 19876384.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2762694
  • [Keywords] NOTNLM ; Effusion / Epstein–Barr virus / human herpes virus-8 / lymphoma
  •  go-up   go-down


52. Wong SS, Vargas J, Thomas A, Fastje C, McLaughlin M, Camponovo R, Lantz RC, Heys J, Witten ML: In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit. Toxicology; 2008 Dec 5;254(1-2):106-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo comparison of epithelial responses for S-8 versus JP-8 jet fuels below permissible exposure limit.
  • This study was designed to characterize and compare the pulmonary effects in distal lung from a low-level exposure to jet propellant-8 fuel (JP-8) and a new synthetic-8 fuel (S-8).
  • A pulmonary function test performed 24h after the final exposure indicated that there was a significant increase in expiratory lung resistance in the S-8 mice, whereas JP-8 mice had significant increases in both inspiratory and expiratory lung resistance compared to control values.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 1999 Dec;20(18):3659-69 [10612293.001]
  • [Cites] Toxicology. 2004 Apr 15;197(2):139-47 [15003324.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):290-8 [11099641.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1075-81 [11943673.001]
  • [Cites] Toxicol Ind Health. 2001 Feb;17(1):23-9 [12004922.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Aug;27(2):170-8 [12151308.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):347-56 [14514957.001]
  • [Cites] J Med Dent Sci. 2003 Sep;50(3):195-202 [15074357.001]
  • [Cites] Toxicol Lett. 2004 Apr 1;149(1-3):301-8 [15093277.001]
  • [Cites] J Toxicol Environ Health A. 2004 Jul 23;67(14):1109-29 [15205027.001]
  • [Cites] Acta Psychiatr Scand. 1979 Jul;60(1):39-49 [474176.001]
  • [Cites] Acta Psychiatr Scand Suppl. 1983;303:55-67 [6575584.001]
  • [Cites] Toxicol Appl Pharmacol. 1984 Aug;75(1):44-51 [6464021.001]
  • [Cites] Scand J Work Environ Health. 1985 Dec;11(6):433-7 [4095521.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):454-64 [3717299.001]
  • [Cites] Toxicol Ind Health. 1995 May-Jun;11(3):325-36 [7482572.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):1-8 [8679213.001]
  • [Cites] J Appl Toxicol. 1996 May-Jun;16(3):197-200 [8818858.001]
  • [Cites] Toxicol Ind Health. 1997 Jan-Feb;13(1):43-55 [9098949.001]
  • [Cites] J Occup Environ Med. 1997 Jul;39(7):623-32 [9253723.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):L229-38 [9950884.001]
  • [Cites] Drug Chem Toxicol. 1999 Feb;22(1):155-64 [10189576.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jul;21(1):44-53 [10385592.001]
  • [Cites] Toxicol Sci. 1999 Sep;51(1):119-25 [10496683.001]
  • [Cites] Phys Med Biol. 2005 Apr 7;50(7):1405-19 [15798332.001]
  • [Cites] J Chromatogr A. 2005 Nov 4;1093(1-2):11-20 [16233866.001]
  • [Cites] Environ Health Perspect. 2006 Feb;114(2):182-5 [16451852.001]
  • [Cites] J Toxicol Sci. 2006 Aug;31(3):219-28 [16960432.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Oct;35(4):479-87 [16690985.001]
  • [Cites] Int J Toxicol. 2007 Jul-Aug;26(4):325-9 [17661223.001]
  • [Cites] J Appl Toxicol. 2008 May;28(4):543-53 [17966119.001]
  • [Cites] Toxicol Pathol. 2000 Sep-Oct;28(5):656-63 [11026600.001]
  • (PMID = 18930109.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES006694-14; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694-14
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hydrocarbons; 0 / JP8 aviation fuel; 0 / S-8 fuel
  • [Other-IDs] NLM/ NIHMS208577; NLM/ PMC2927360
  •  go-up   go-down


53. Rotoli BM, Closs EI, Barilli A, Visigalli R, Simon A, Habermeier A, Bianchi N, Gambari R, Gazzola GC, Bussolati O, Dall'Asta V: Arginine transport in human erythroid cells: discrimination of CAT1 and 4F2hc/y+LAT2 roles. Pflugers Arch; 2009 Oct;458(6):1163-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine transport in human erythroid cells: discrimination of CAT1 and 4F2hc/y+LAT2 roles.
  • Since arginine metabolites, such as nitric oxide and polyamines, influence the expression of genes involved in erythroid differentiation, the transport of the cationic amino acid may play an important role in erythroid cells.
  • Using erythroleukemia K562 cells and normal erythroid precursors, we demonstrate here that arginine transport in human erythroid cells is due to the additive contributions of a leucine-sensitive and leucine-insensitive component.
  • Lastly, silencing of SLC7A6, the gene for y(+)LAT2, lowers arginine transport and doubles the intracellular content of the cationic amino acid in K562 cells.
  • We conclude that arginine transport in human erythroid cells is due to both system y(+) (CAT1 transporter) and system y(+)L (4F2hc/y(+)LAT2 isoform), which mainly contribute, respectively, to the influx and to the efflux of the cationic amino acid.
  • [MeSH-major] Antigens, CD98 Heavy Chain / physiology. Erythroid Precursor Cells / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / physiology. Amino Acid Transport System y+ / metabolism. Amino Acid Transport Systems, Basic / physiology. Animals. Arginine / metabolism. Cationic Amino Acid Transporter 1 / metabolism. Gene Silencing. Humans. K562 Cells. Large Neutral Amino Acid-Transporter 1 / metabolism. Oocytes / metabolism. Xenopus laevis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Pharm Bull. 2006 Feb;29(2):234-9 [16462024.001]
  • [Cites] Blood. 2004 May 15;103(10 ):3945-50 [14764535.001]
  • [Cites] Biochem J. 2000 Aug 1;349 Pt 3:787-95 [10903140.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):231-9 [12531879.001]
  • [Cites] Physiol Rev. 1998 Apr;78(2):487-545 [9562037.001]
  • [Cites] Physiol Rev. 2008 Jan;88(1):249-86 [18195088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1847-52 [11172039.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Jul;37(1):105-12 [17363779.001]
  • [Cites] Trends Immunol. 2003 Jun;24(6):302-6 [12810105.001]
  • [Cites] Am J Physiol. 1999 Apr;276(4 Pt 1):C865-72 [10199817.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):532-42 [14770310.001]
  • [Cites] Curr Med Chem. 2007;14(2):199-212 [17266579.001]
  • [Cites] Blood. 2008 Aug 1;112(3):470-8 [18650462.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jan;282(1):C134-43 [11742806.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):914-25 [9106662.001]
  • [Cites] Blood. 1975 Mar;45(3):321-34 [163658.001]
  • [Cites] J Physiol. 1993 Aug;468:753-66 [8254535.001]
  • [Cites] Adv Perit Dial. 2007;23:48-50 [17886602.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1117-23 [17993617.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1352-6 [16210335.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1768(6):1479-87 [17397797.001]
  • [Cites] FASEB J. 2005 May;19(7):810-2 [15746185.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1276-81 [12738678.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):177-81 [15280038.001]
  • [Cites] Mol Genet Metab. 2007 Jan;90(1):37-41 [16935537.001]
  • [Cites] J Physiol. 1992 Aug;454:491-501 [1474499.001]
  • [Cites] Biochim Biophys Acta. 2004 Jan 28;1660(1-2):138-43 [14757229.001]
  • [Cites] J Leukoc Biol. 2009 Feb;85(2):268-77 [19008294.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2943-51 [16368881.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Dec;279(6):C1829-37 [11078698.001]
  • [Cites] Blood Cells Mol Dis. 2009 Jul-Aug;43(1):74-80 [19329339.001]
  • (PMID = 19562367.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP07257
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Amino Acid Transport System y+; 0 / Amino Acid Transport Systems, Basic; 0 / Antigens, CD98 Heavy Chain; 0 / Cationic Amino Acid Transporter 1; 0 / LAT2 protein, human; 0 / Large Neutral Amino Acid-Transporter 1; 0 / SLC3A2 protein, human; 0 / SLC7A6 protein, human; 94ZLA3W45F / Arginine
  •  go-up   go-down


54. Kawai T, Choi U, Whiting-Theobald NL, Linton GF, Brenner S, Sechler JM, Murphy PM, Malech HL: Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol; 2005 Apr;33(4):460-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome.
  • OBJECTIVE: WHIM (warts, hypogammaglobulinemia, recurrent bacterial infection, myelokathexis) syndrome is an autosomal dominant immune deficiency with severe chronic neutropenia and marrow neutrophil apoptosis.
  • Control vectors included similar constructs with wild-type CXCR4 (WT-CXCR4) or only GFP.
  • RESULTS: Healthy human CD34+ cells and/or human erythroleukemia K562 cells transduced to express mutated CXCR4, WT-CXCR4, or GFP alone demonstrated that mutated CXCR4 was associated with enhanced calcium flux and enhanced migration.
  • CONCLUSION: We propose that decreased internalization of WHIM-associated mutated CXCR4 leads to prolongation/enhancement of signaling in response to SDF1 and that this may provide the biochemical basis for the autosomal dominant abnormalities of cell trafficking and function associated with WHIM syndrome.
  • [MeSH-minor] Agammaglobulinemia. Bacterial Infections. Cell Line. Chemokine CXCL12. Chemokines, CXC / pharmacology. Dose-Response Relationship, Drug. Humans. Kinetics. Neutropenia. Signal Transduction / drug effects. Syndrome. Transduction, Genetic. Warts

  • Genetics Home Reference. consumer health - CXCR4 gene.
  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781337.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4
  •  go-up   go-down


55. Coyle AT, Kinsella BT: Characterization of promoter 3 of the human thromboxane A receptor gene. A functional AP-1 and octamer motif are required for basal promoter activity. FEBS J; 2005 Feb;272(4):1036-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of promoter 3 of the human thromboxane A receptor gene. A functional AP-1 and octamer motif are required for basal promoter activity.
  • Hence, the ability of Prm3 and a series of Prm3 deleted/mutated subfragments to direct reporter gene expression in human erythroleukemia 92.1.7 and human embryonic kidney 293 cells was investigated.
  • Furthermore, three distinct regulatory regions comprising of an upstream repressor sequence, located between -404 to -320, and two positive regulatory regions required for efficient basal gene expression, located between -154 to -106 and -50 to +1, were identified within the core Prm3.
  • [MeSH-major] Gene Expression / physiology. Promoter Regions, Genetic. Receptors, Thromboxane A2, Prostaglandin H2 / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691336.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Octamer Transcription Factor-1; 0 / Octamer Transcription Factor-2; 0 / POU2F1 protein, human; 0 / POU2F2 protein, human; 0 / Phorbol Esters; 0 / Receptors, Thromboxane A2, Prostaglandin H2; 0 / Transcription Factor AP-1; 0 / Transcription Factors; 20839-06-9 / phorbol-12-myristate
  •  go-up   go-down


56. Lin IJ, Zhou Z, Crusselle-Davis VJ, Moghimi B, Gandhi K, Anantharaman A, Pantic D, Huang S, Jayandharan G, Zhong L, Srivastava A, Bungert J: Calpeptin increases the activity of upstream stimulatory factor and induces high level globin gene expression in erythroid cells. J Biol Chem; 2009 Jul 24;284(30):20130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calpeptin increases the activity of upstream stimulatory factor and induces high level globin gene expression in erythroid cells.
  • Differentiation of erythroid cells is regulated by cell signaling pathways including those that change the intracellular concentration of calcium.
  • We show here that the protein levels of upstream stimulatory factor (USF) increase during differentiation of murine erythroleukemia (MEL) cells.
  • Treatment of MEL cells with the specific calpain inhibitor calpeptin increased the levels of USF and strongly induced expression of the adult alpha- and beta-globin genes.
  • The induction of globin gene expression was associated with an increase in the association of USF and RNA po ly mer ase II with regulatory elements of the beta-globin gene locus.
  • Calpeptin also induced high level alpha- and beta-globin gene expression in primary CD71-positive erythroid progenitor cells.
  • The combined data suggest that inhibition of calpain activity is required for erythroid differentiation-associated increase in globin gene expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):369-78 [8995271.001]
  • [Cites] Nucleic Acids Res. 1993 Nov 11;21(22):5092-100 [8255762.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50350-7 [15385559.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):146-55 [15752978.001]
  • [Cites] Pigment Cell Res. 2005 Oct;18(5):337-48 [16162174.001]
  • [Cites] Cell Biochem Biophys. 2006;45(2):147-56 [16757815.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6832-43 [16943425.001]
  • [Cites] Science. 2006 Oct 6;314(5796):122-5 [17023658.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):1037-46 [17272500.001]
  • [Cites] FEBS J. 2007 Dec;274(23):6065-73 [17970752.001]
  • [Cites] Mol Cell. 2007 Dec 14;28(5):810-22 [18082606.001]
  • [Cites] Science. 2007 Dec 21;318(5858):1920-3 [18063756.001]
  • [Cites] Curr Opin Immunol. 2008 Jun;20(3):250-8 [18515054.001]
  • [Cites] Exp Hematol. 2008 Sep;36(9):1057-72 [18718415.001]
  • [Cites] Biol Reprod. 2009 Jan;80(1):24-33 [18768914.001]
  • [Cites] Nature. 2009 Feb 26;457(7233):1103-8 [19242469.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1140-8 [10648599.001]
  • [Cites] J Exp Med. 2000 Nov 20;192(10):1479-90 [11085749.001]
  • [Cites] Biol Chem. 2002 May;383(5):757-64 [12108540.001]
  • [Cites] Cell. 2002 Nov 15;111(4):529-41 [12437926.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):1292-301 [12582249.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):731-801 [12843408.001]
  • [Cites] Cell. 1976 Oct;9(2):221-9 [975244.001]
  • [Cites] J Cell Biol. 1981 Aug;90(2):542-4 [6793600.001]
  • [Cites] J Biol Chem. 1985 Apr 25;260(8):4884-9 [3857230.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1362-70 [2001459.001]
  • [Cites] Nature. 1993 Jan 28;361(6410):315-25 [8381210.001]
  • [Cites] Biochim Biophys Acta. 1993 Aug 18;1178(2):207-14 [8347679.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18824-34 [8360172.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):355-9 [8377828.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):1-10 [15541720.001]
  • (PMID = 19491096.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356; United States / NIDDK NIH HHS / DK / DK052356-15A1; United States / NHLBI NIH HHS / HL / R01 HL090589; United States / NIDDK NIH HHS / DK / DK052356; United States / NIDDK NIH HHS / DK / R01 DK052356-10; United States / NIDDK NIH HHS / DK / R01 DK052356-15A1; United States / NHLBI NIH HHS / HL / HL090589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Upstream Stimulatory Factors; 117591-20-5 / calpeptin; 9004-22-2 / Globins; EC 2.7.7.- / RNA Polymerase II; EC 3.4.22.- / Calpain; EC 3.4.22.- / m-calpain
  • [Other-IDs] NLM/ PMC2740439
  •  go-up   go-down


57. Kern RM, Yang Z, Kim PS, Grody WW, Iyer RK, Cederbaum SD: Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines. Mol Genet Metab; 2007 Jan;90(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperargininemia is a urea cycle disorder caused by mutations in the gene for arginase I (AI) resulting in elevated blood arginine and ammonia levels.
  • The elevated arginine levels induce the second arginase (AII) in patient kidney and kidney tissue culture.
  • It has been shown that NaPB increases expression of some target genes and we tested its effect on arginase induction.
  • In some cell lines, NaPB increased arginase activity up to fivefold depending on dose (1-5 mM) and exposure time (2-5 days); control and NaPB activities, respectively, are: erythroleukemia, HEL, 0.06 and 0.31 U/mg, and K562, 0.46 and 1.74 U/mg; embryonic kidney, HEK293, 1.98 and 3.58 U/mg; breast adenocarcinoma, MDA-MB-468, 1.11 and 4.06 U/mg; and prostate adenocarcinoma, PC-3, 0.55 and 3.20 U/mg.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935537.001).
  • [ISSN] 1096-7192
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-0402411; United States / NICHD NIH HHS / HD / HD-06576; United States / NICHD NIH HHS / HD / HD-36415
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Phenylbutyrates; 7WY7YBI87E / 4-phenylbutyric acid; EC 3.5.3.1 / Arg2 protein, mouse; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


58. De Vriese C, Grégoire F, De Neef P, Robberecht P, Delporte C: Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. Endocrinology; 2005 Mar;146(3):1514-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ghrelin levels were not affected after 24 h treatment with sodium butyrate, phorbol 12-myristate 13-acetate, or forskolin, but a significant 3-fold increase in desoctanoylated ghrelin was detected in the culture medium after 48 h treatment with sodium butyrate.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / metabolism. Peptide Hormones / biosynthesis. Peptide Hormones / physiology

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15564328.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Culture Media; 0 / Ghrelin; 0 / Peptide Hormones; 0 / Peptides; 0 / RNA, Messenger; 7G33012534 / Sodium Oxybate; EC 3.1.1.- / Butyrylcholinesterase; EC 3.1.1.- / Carboxylic Ester Hydrolases
  •  go-up   go-down


59. Bruchova-Votavova H, Yoon D, Prchal JT: miR-451 enhances erythroid differentiation in K562 cells. Leuk Lymphoma; 2010 Apr;51(4):686-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-451 enhances erythroid differentiation in K562 cells.
  • Erythropoiesis is a multistep process regulated at the molecular level by intrinsic and extrinsic factors including microRNAs (miRNAs).
  • We previously identified aberrant expression of miR-451 and miR-150 in polycythemia vera (PV) erythroid differentiating cells.
  • To address the functional relevance of these miRNAs in erythroid differentiation, we employed synthetic mimics and inhibitors of miR-451 and miR-150 in erythroid differentiating K562 cells.
  • We observed that miR-451 up-regulation and miR-150 down-regulation are associated with progression of erythroid maturation in K562 cells.
  • Further, enforced expression of miR-451 promoted erythroid differentiation.
  • Our results demonstrate that miR-451 is involved in the regulation of erythroid differentiation and functions as an enhancer of differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218812.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108671; United States / NCI NIH HHS / CA / 1P01CA108671-O1A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN150 microRNA, human; 0 / MIRN451 microRNA, human; 0 / MicroRNAs; 743LRP9S7N / Hemin
  •  go-up   go-down


60. Riggleman RA, Douglas JF, de Pablo JJ: Characterization of the potential energy landscape of an antiplasticized polymer. Phys Rev E Stat Nonlin Soft Matter Phys; 2007 Jul;76(1 Pt 1):011504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nature of the individual transitions on the potential energy landscape (PEL) associated with particle motion are directly examined for model fragile glass-forming polymer melts, and the results are compared to those of an antiplasticized polymer system.
  • In the present work, we find that the antiplasticizing molecules reduce the energy barriers for relaxation compared to the pure polymer, implying that the antiplasticized system has smaller barriers to overcome in order to explore its configuration space.
  • Notably, the stringlike collective motion identified by our PEL analysis corresponds to incremental displacements that occur within larger-scale stringlike particle displacement processes associated with PEL metabasin transitions that mediate structural relaxation.
  • Film confinement makes the energy barriers substantially smaller in the pure polymer, while it has little effect on the energy barriers in the antiplasticized system.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17677447.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Chadburn A, Hyjek EM, Tam W, Liu Y, Rengifo T, Cesarman E, Knowles DM: Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD). Histopathology; 2008 Nov;53(5):513-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).
  • AIMS: Kaposi sarcoma herpesvirus (KSHV) is aetiologically related to Kaposi sarcoma, classical and extracavitary primary effusion lymphoma (PEL; EC-PEL) and multicentric Castleman disease (MCD), entities preferentially occurring in HIV-infected individuals.
  • Characterization of HIV-associated PELs/EC-PELs suggests that the KSHV-infected malignant cells originate from a pre-terminal stage of B-cell differentiation.
  • However, only limited phenotypic studies have been performed on HIV+ MCD, including for PR domain containing 1 with zinc finger domain/B lymphocyte-induced maturation protein 1 (PRDM1/BLIMP1), a key regulator of terminal B-cell differentiation.
  • METHODS AND RESULTS: Double immunohistochemistry and immunohistochemistry-in situ hybridization were used to characterize the KSHV-infected cells in MCD; the results were compared with the phenotypic profiles of 39 PELs/EC-PELs and seven PEL cell lines.
  • Whereas the immunophenotype of KSHV-infected cells in MCD and malignant KSHV+ PEL cells was similar (PAX5, Bcl-6-; PRDM1/BLIMP1, IRF4/MUM1+; Ki67+), the MCD KSHV-infected cells differed, as they expressed OCT2, cytoplasmic lambda immunoglobulin; variably expressed CD27; lacked CD138; and were Epstein-Barr virus negative.
  • CONCLUSIONS: Although both PEL and MCD originate from KSHV-infected pre-terminally differentiated B cells, these findings, with previously reported genetic studies, indicate HIV+ MCD may arise from extrafollicular B cells, whereas PELs may originate from cells that have traversed the germinal centre.
  • [MeSH-major] B-Lymphocytes / virology. Giant Lymph Node Hyperplasia / virology. HIV Infections / complications. Herpesviridae Infections / virology. Herpesvirus 8, Human. Lymphoma, Primary Effusion / virology


62. Kulkarni AP, Mittal SP, Devasagayam TP, Pal JK: Oxidative stress perturbs cell proliferation in human K562 cells by modulating protein synthesis and cell cycle. Free Radic Res; 2009;43(11):1090-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidative stress leads to perturbation of a variety of cellular processes resulting in inhibition of cell proliferation.
  • The results indicated that oxidative stress leads to a significant decrease in the rate of protein synthesis caused due to induced activation as well as expression of the erythroid cell-specific eIF-2alpha kinase, called the Heme Regulated Inhibitor (HRI).
  • Elevated levels of HRI expression and activity were accompanied by increased lipid peroxidation and decreased cell proliferation.
  • Thus, the data provides the mechanism of inhibition of protein synthesis and perturbation of a cell cycle regulatory protein leading to inhibition of cell proliferation in K562 cells during oxidative stress.
  • [MeSH-major] Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Oxidative Stress / physiology

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669995.001).
  • [ISSN] 1029-2470
  • [Journal-full-title] Free radical research
  • [ISO-abbreviation] Free Radic. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amidines; 13217-66-8 / 2,2'-azobis(2-amidinopropane); BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


63. Yang Y, Létard S, Borge L, Chaix A, Hanssens K, Lopez S, Vita M, Finetti P, Birnbaum D, Bertucci F, Gomez S, de Sepulveda P, Dubreuil P: Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood; 2010 Aug 19;116(7):1114-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PTD mutants failed to support colony formation and erythropoietin-mediated erythroid differentiation.
  • Consistently, AKT inhibitor suppressed ECD mutant-dependent proliferation, clonogenicity, and erythroid differentiation.
  • Expression of myristoylated AKT restored erythroid differentiation in EML-PTD cells, suggesting the differential role of AKT in those mutants.
  • [MeSH-minor] Adult. Animals. Apoptosis. Blotting, Western. Cells, Cultured. Child. Fibroblasts / cytology. Fibroblasts / metabolism. Flow Cytometry. Humans. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Lymphocytes / metabolism. Mast Cells / metabolism. Mice. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. Rats. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Mast cell disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484085.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


64. Zuclich JA, Lund DJ, Stuck BE: Wavelength dependence of ocular damage thresholds in the near-ir to far-ir transition region: proposed revisions to MPES. Health Phys; 2007 Jan;92(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report summarizes the results of a series of infrared (IR) laser-induced ocular damage studies conducted over the past decade.
  • The studies examined retinal, lens, and corneal effects of laser exposures in the near-IR to far-IR transition region (wavelengths from 1.3-1.4 mum with exposure durations ranging from Q-switched to continuous wave).
  • The corneal and retinal damage thresholds are tabulated for all pulsewidth regimes, and the wavelength dependence of the IR thresholds is discussed and contrasted to laser safety standard maximum permissible exposure limits.
  • The analysis suggests that the current maximum permissible exposure limits could be beneficially revised to (1) relax the IR limits over wavelength ranges where unusually high safety margins may unintentionally hinder applications of recently developed military and telecommunications laser systems;.
  • (2) replace step-function discontinuities in the IR limits by continuously varying analytical functions of wavelength and pulsewidth which more closely follow the trends of the experimental retinal (for point-source laser exposures) and corneal ED50 threshold data; and (3) result in an overall simplification of the permissible exposure limits over the wavelength range from 1.2-2.6 mum.
  • A specific proposal for amending the IR maximum permissible exposure limits over this wavelength range is presented.
  • [MeSH-major] Eye Injuries / diagnosis. Eye Injuries / etiology. Infrared Rays / adverse effects. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiation Protection / standards. Radiometry / standards

  • MedlinePlus Health Information. consumer health - Eye Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164595.001).
  • [ISSN] 0017-9078
  • [Journal-full-title] Health physics
  • [ISO-abbreviation] Health Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


65. Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF, Keller JR: C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood; 2006 Jun 1;107(11):4308-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation.
  • C/EBPalpha is an essential transcription factor required for myeloid differentiation.
  • We found increased numbers of erythroid progenitors and erythroid cells in C/EBPalpha(-/-) fetal liver (FL).
  • Also, enforced expression of C/EBPalpha in hematopoietic stem cells resulted in a loss of erythroid progenitors and an increase in myeloid cells by inhibition of erythroid development and inducing myeloid differentiation.
  • Conditional expression of C/EBPalpha in murine erythroleukemia (MEL) cells induced myeloid-specific genes, while inhibiting erythroid-specific gene expression including erythropoietin receptor (EpoR), which suggests a novel mechanism to determine hematopoietic cell fate.
  • Thus, C/EBPalpha functions in hematopoietic cell fate decisions by the dual actions of inhibiting erythroid and inducing myeloid gene expression in multipotential progenitors.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1997 Jan 9;14(1):123-31 [9010239.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):5986-97 [10913181.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):6014-22 [9315660.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Gene Expr. 1998;7(1):25-38 [9572395.001]
  • [Cites] J Biol Chem. 1998 Jun 12;273(24):14796-804 [9614080.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4301-14 [9632814.001]
  • [Cites] Exp Cell Res. 1998 Nov 25;245(1):186-94 [9828115.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):263-70 [11242107.001]
  • [Cites] Blood. 2001 Jul 15;98(2):475-7 [11435319.001]
  • [Cites] Cell. 2001 Oct 19;107(2):247-58 [11672531.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):817-28 [11684017.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):48-58 [11753385.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):886-900 [11784864.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1332-40 [11830484.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4406-12 [12036869.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Exp Hematol. 2002 Jul;30(7):649-58 [12135661.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2279-88 [12239135.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2206-14 [12406909.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2097-101 [12805554.001]
  • [Cites] Immunity. 2003 Sep;19(3):451-62 [14499119.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):1029-36 [12958595.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7585-99 [14560005.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3238-50 [15060147.001]
  • [Cites] Blood. 2004 May 1;103(9):3326-35 [14715640.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1639-47 [15073037.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Feb;68(2):378-82 [5277089.001]
  • [Cites] J Virol. 1990 Apr;64(4):1517-22 [2157040.001]
  • [Cites] Mol Cell Biol. 1993 Jan;13(1):98-104 [8417366.001]
  • [Cites] J Biol Chem. 1994 Feb 18;269(7):5078-84 [8106486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5952-6 [8016095.001]
  • [Cites] Genes Dev. 1994 Dec 1;8(23):2831-41 [7995521.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17939-46 [7629100.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5830-45 [7565736.001]
  • [Cites] Blood. 1996 Jan 1;87(1):102-11 [8547631.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1231-40 [8622667.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3385-91 [8631937.001]
  • [Cites] Mol Cell Biol. 1996 Jun;16(6):2898-905 [8649400.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1234-47 [8695841.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1398-411 [10364157.001]
  • [Cites] Immunity. 2004 Dec;21(6):853-63 [15589173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13186-90 [10557295.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Science. 2000 May 26;288(5470):1439-41 [10827957.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):569-74 [9012825.001]
  • (PMID = 16469877.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Receptors, Erythropoietin
  • [Other-IDs] NLM/ PMC1895788
  •  go-up   go-down


66. Grossmann C, Ganem D: Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology; 2008 May 25;375(1):94-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latent v-FLIP gene is a strong activator of NFkappaB, and in primary effusion lymphoma (PEL) cells, blockade of NFkappaB activation is associated with enhanced lytic gene expression, while overexpression of p65 impairs expression of reporter genes driven by lytic promoters.
  • In accord with earlier work, we find that inhibition of NFkappaB signaling in PEL cells is associated with enhanced lytic reactivation of KSHV.
  • Similarly, in de novo KSHV infection of primary endothelial cells, inhibition of NFkappaB signaling leads to an increase in lytic gene expression and enhanced virion production.
  • Moreover, if NFkappaB activation is always inhibitory to lytic gene expression, one might expect its activation to be suppressed during the lytic cycle.
  • Together these data indicate that (i) the relationship of NFkappaB activation to latency and lytic reactivation is not uniform, but is dependent on the cellular context; and (ii) even though NFkappaB activation is inhibitory to lytic gene expression in some contexts, such inhibition is at least partially bypassed or overridden during lytic growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Annu Rev Pathol. 2006;1:273-96 [18039116.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] J Virol. 2001 Jun;75(12):5614-26 [11356969.001]
  • [Cites] J Virol. 2002 Mar;76(5):2440-8 [11836422.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13745-51 [11830587.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] J Cell Sci. 2003 Sep 15;116(Pt 18):3721-8 [12890756.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):993-1003 [15067035.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5770-80 [15235582.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Am J Epidemiol. 1998 Feb 1;147(3):217-21 [9482495.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):211-6 [9653098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3295-302 [16380446.001]
  • [Cites] J Virol. 2006 Jul;80(14):7179-85 [16809323.001]
  • [Cites] J Virol. 2001 Jan;75(1):429-38 [11119611.001]
  • (PMID = 18321555.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA073506-10; United States / NCI NIH HHS / CA / R01 CA073506; United States / NCI NIH HHS / CA / R01 CA073506-10
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B
  • [Other-IDs] NLM/ NIHMS51306; NLM/ PMC2822626
  •  go-up   go-down


67. Daesslé LW, Lugo-Ibarra KC, Tobschall HJ, Melo M, Gutiérrez-Galindo EA, García-Hernández J, Alvarez LG: Accumulation of as, pb, and cu associated with the recent sedimentary processes in the colorado delta, South of the United States-Mexico boundary. Arch Environ Contam Toxicol; 2009 May;56(4):680-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flushing by river and tide flows appear to be responsible of a lower pollutant deposition in the CR compared to the adjacent Hardy River (HR).
  • Arsenic in the buried clay units of the HR has concentrations above the probable toxic effect level (PEL) for dwelling organisms, with maximum concentrations of 30 microg g(-1).

  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797954.001).
  • [ISSN] 1432-0703
  • [Journal-full-title] Archives of environmental contamination and toxicology
  • [ISO-abbreviation] Arch. Environ. Contam. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Soil Pollutants; 0 / Water Pollutants, Chemical; 2P299V784P / Lead; 789U1901C5 / Copper
  •  go-up   go-down


68. Park KS, Kang SY, Lee WI: [HLA-B27 subtypes in Korean patients with ankylosing spondylitis]. Korean J Lab Med; 2008 Feb;28(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pel-Freez SSP Unitray HLA-B*27 kit (Dynal Biotech, USA) including 16 primers was used to define HLA-B27 subtypes from B*2701 to B*2735.
  • [MeSH-major] HLA-B27 Antigen / genetics. Spondylitis, Ankylosing / diagnosis
  • [MeSH-minor] Adult. Alleles. Female. Gene Frequency. Genotype. Humans. Korea / epidemiology. Male. Polymerase Chain Reaction. Polymorphism, Genetic. Reagent Kits, Diagnostic

  • Genetic Alliance. consumer health - Ankylosing Spondylitis.
  • Genetic Alliance. consumer health - Spondylitis.
  • MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309255.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / HLA-B27 Antigen; 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


69. Watanabe Y, Fukui N, Nunokawa A, Muratake T, Kaneko N, Kitamura H, Someya T: No association between the ERBB3 gene and schizophrenia in a Japanese population. Neurosci Res; 2007 Apr;57(4):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association between the ERBB3 gene and schizophrenia in a Japanese population.
  • There is cumulative evidence that neuregulin 1 (NRG1) is a susceptibility gene for schizophrenia.
  • Postmortem studies on brains from schizophrenia patients have revealed changes in the mRNA expression levels of v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), one of the NRG1 receptor genes.
  • To assess whether the ERBB3 gene could be implicated in vulnerability to schizophrenia, we conducted a case-control (399 patients and 438 controls) association study in Japanese subjects.
  • [MeSH-major] Genetic Predisposition to Disease. Receptor, ErbB-3 / genetics. Schizophrenia / genetics
  • [MeSH-minor] Adult. Case-Control Studies. Female. Gene Frequency. Genotype. Humans. Japan / epidemiology. Linkage Disequilibrium. Male. Middle Aged. Polymorphism, Single Nucleotide


70. Herok R, Konopacka M, Polanska J, Swierniak A, Rogolinski J, Jaksik R, Hancock R, Rzeszowska-Wolny J: Bystander effects induced by medium from irradiated cells: similar transcriptome responses in irradiated and bystander K562 cells. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):244-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This work analyzes and compares changes in global transcript levels induced by direct irradiation and by bystander effects in K562 (human erythroleukemia) cells.
  • RESULTS: The level of the majority (72%) of transcripts changed similarly (increase, decrease, or no change) in cells grown in irradiation-conditioned medium or irradiated, whereas only 0.6% showed an opposite response.
  • Transcript level changes in bystander and irradiated cells were significantly different from those in untreated cells grown for the same amount of time and were confirmed by quantitative reverse transcriptase-polymerase chain reaction for selected genes.
  • [MeSH-major] Bystander Effect / radiation effects. Culture Media, Conditioned / pharmacology. Gene Expression Profiling / methods. K562 Cells / radiation effects. Signal Transduction / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394856.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned
  •  go-up   go-down


71. Peñuelas S, Noé V, Morales R, Ciudad CJ: Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit; 2005 Jan;11(1):BR6-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
  • To identify potential targets as modulators in MTX chemotherapy, we determined gene expression profiles upon MTX treatment.
  • MATERIAL/METHODS: Expression profiles in human erythroleukemia K562 cells were determined after short treatment with MTX or once resistance to MTX was established.
  • Specific software (Atlas Image 2.0.1 and Gene Spring 6.1) was used to analyze the expression level for each gene in each condition.
  • RESULTS: Differentially expressed genes were selected considering a factor of 2 with respect to their expression in control cells.
  • Eight genes were found to be overexpressed and 14 underexpressed both in MTX-treated and resistant cells.
  • Among the overexpressed genes we chose 5'-monophosphate dehydrogenase (IMPDH2) for further validation.
  • Changes in IMPDH2 mRNA levels were confirmed and functional analyses were performed by inhibiting IMPDH with either benzamide riboside, mycophenolic acid, or tiazofurin.
  • [MeSH-minor] Cell Survival / drug effects. Gene Expression Profiling. Humans. K562 Cells. Leukemia, Erythroblastic, Acute. Oligonucleotide Array Sequence Analysis. Transcription, Genetic

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614187.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.1.1.205 / IMP Dehydrogenase; EC 1.1.1.205 / IMPDH2 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


72. Das DK: Serous effusions in malignant lymphomas: a review. Diagn Cytopathol; 2006 May;34(5):335-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous effusions in malignant lymphomas: a review.
  • Although the frequency of pleural effusion is 20-30% in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD), the involvement of peritoneal and pericardial cavities is uncommon.
  • Cytologic features of specific lymphoma subtypes such as lymphoblastic lymphoma, follicular center cell lymphoma, including Burkitt-type lymphoma, marginal zone lymphoma, MALT lymphoma, and anaplastic large-cell lymphoma, etc., have been described in the literature.
  • ICC not only distinguishes lymphomas from reactive lymphocytoses and SRCTs, it significantly modifies the morphologic diagnosis to achieve a better classification of lymphomas.
  • Morphometry also distinguishes reactive lymphocytoses from malignant lymphoma with a high degree of sensitivity (>85%) and specificity (>95%).
  • Although lymphomas rarely present as serous effusions without the involvement of other thoracic and extrathoracic sites, a small group of lymphomas called primary effusion lymphomas (PEL) exhibit exclusive or dominant involvement of serous cavities, without a detectable solid tumor mass.
  • Cytomorphologically, PEL is usually a large-cell lymphoma, which appears to bridge features of large-cell immunoblastic and anaplastic large-cell lymphoma (ALCL).
  • The presence of pleural effusion at the time of presentation is not only associated with extremely poor outcome of lymphomas, it is also a predictor of disease relapse after chemotherapy and decreased survival.
  • In such situations, cytology along with ancillary studies not only gives a quick diagnosis of lymphoma, but also offers prognostically significant information such as classification of lymphomas, its grade and immunophenotype, and presence/absence of viral DNAs and tumor lysis syndrome.
  • [MeSH-major] Cytodiagnosis / methods. Lymphoma / complications. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Ascitic Fluid / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphocytosis / pathology. Male. Pericardial Effusion / etiology. Pericardial Effusion / pathology. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604559.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


73. Coupland SE, Charlotte F, Mansour G, Maloum K, Hummel M, Stein H: HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man. Am J Surg Pathol; 2005 May;29(5):647-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man.
  • Primary effusion lymphoma (PEL) is an uncommon large cell lymphoma, usually seen in human immunodeficiency virus (HIV)-infected patients.
  • PEL is characterized by various clinical, histomorphologic, and immunophenotypical features, and is associated with the human herpes virus 8 (HHV-8).
  • PEL may present as either a body cavity-based lymphomatous effusion or a solid tumor mass.
  • Most so-called "solid PEL" usually have an extranodal location; exceptionally rarely, they occur in lymph nodes.
  • The majority of PEL consist of malignant cells of B-cell genotype; seldom they are of T-cell origin.
  • We report a rare case of HHV-8-associated "solid PEL" of T-cell type in a 41-year-old HIV-seropositive man with a concomitant peritoneal effusion.
  • The T-cell lymphoma was diagnosed on the basis of morphologic, immunophenotypic, and molecular findings of a lymph node biopsy.
  • The tumor cells strongly expressed CD45R0, CD7, CD43, MUM1/IRF4, CD30, HHV-8, and EBER, and demonstrated a clonal rearrangement of T-cell receptor-gamma chain gene.
  • The following case provides another example of a lymph node-based "solid" PEL, demonstrating the variety within the spectrum of HHV-8-associated lymphoma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Clone Cells. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832089.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Inoue Y, Tsushima H, Ando K, Sawayama Y, Sakai M, Yamasaki R, Matsuo E, Tsutsumi C, Imaizumi Y, Iwanaga M, Imanishi D, Taguchi J, Miyazaki Y, Tomonaga M: Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein-3alpha/CCL20 is induced by inflammatory cytokines. Exp Hematol; 2006 Jan;34(1):19-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein-3alpha/CCL20 is induced by inflammatory cytokines.
  • OBJECTIVE: Normal and malignant hematopoietic cells are shown to express and secrete various cytokines and chemokines, some of which are believed to play an important role in normal and abnormal hematopoiesis in an autocrine/paracrine manner.
  • To explore the possibility of a cytokine/chemokine network participating in the pathophysiology of anemic disorders, we evaluated the ability of inflammatory cytokines to induce chemokine expression using erythroid progenitor cells.
  • METHODS: Erythropoietin-dependent human leukemia cell line AS-E2 was used as a model of erythroid colony-forming unit (CFU-E) cells.
  • Luciferase assay revealed that these cytokines could upregulate promoter activity of the MIP-3alpha gene, possibly through the NF-kappaB pathway.
  • CONCLUSION: These data suggest that inflammatory cytokine-stimulated erythroid progenitors secrete MIP-3alpha, which may function in an autocrine/paracrine manner.
  • Furthermore, the existence of intracellular CCR6 suggests the involvement in cytokine signaling of a MIP-3alpha-dependent internal autocrine mechanism.
  • These mechanisms may play a role in pathophysiology of anemic disorders, such as secondary anemia and bone marrow failure syndromes.
  • [MeSH-major] Chemokines / genetics. Chemokines, CC / metabolism. Cytokines / pharmacology. Erythroid Precursor Cells / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Macrophage Inflammatory Proteins / metabolism
  • [MeSH-minor] Cell Line, Tumor. Chemokine CCL20. Enzyme-Linked Immunosorbent Assay. Erythropoietin / metabolism. Gene Expression Regulation / drug effects. Gene Expression Regulation / immunology. Humans. Inflammation. Interleukin-1 / pharmacology. Promoter Regions, Genetic / drug effects. Promoter Regions, Genetic / physiology. RNA, Messenger / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, CCR6. Receptors, Chemokine / drug effects. Receptors, Chemokine / metabolism. Tumor Necrosis Factor-alpha / pharmacology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413387.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CCL20 protein, human; 0 / CCR6 protein, human; 0 / Chemokine CCL20; 0 / Chemokines; 0 / Chemokines, CC; 0 / Cytokines; 0 / Interleukin-1; 0 / Macrophage Inflammatory Proteins; 0 / RNA, Messenger; 0 / Receptors, CCR6; 0 / Receptors, Chemokine; 0 / Tumor Necrosis Factor-alpha; 11096-26-7 / Erythropoietin
  •  go-up   go-down


75. Dombrowski F, Klotz L, Bannasch P, Evert M: Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development. Diabetologia; 2007 Dec;50(12):2580-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Rats (n = 850), which were either spontaneously diabetic, streptozotocin-diabetic or normoglycaemic, were examined with special reference to Armanni-Ebstein lesions (AEL).
  • RESULTS: Irrespective of the cause of diabetes, diabetic but not normoglycaemic rats developed typical glycogenotic clear-cell AEL.
  • AEL showed strong proliferative activity, which was nearly completely inhibited by EGF receptor blockade (Gefitinib treatment).
  • Many findings suggested a stepwise development of RCCs from AEL.
  • In contrast to the proximal tubules, the distal tubular system, including glycogenotic AEL, had the same levels of enzyme activities as RCC (e.g. high glycogen phosphorylase and synthase activity, lack of glucose 6-phosphatase activity) and the same expression patterns of cytokeratin 7 and several growth factors, along with their receptors and signal transduction proteins (TGF-alpha, EGF receptor, IGF-I, IGF-I receptor, IGF-II receptor, insulin receptor substrate 1, v-raf-1 murine leukemia viral oncogene homologue 1 and mitogen activated protein kinase kinase 1).
  • In addition, direct morphological transitions between distal tubules, AEL and RCCs were frequently observed.
  • All these findings indicate a common origin and a precursor-product relationship of AEL and RCCs.
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Intercellular Signaling Peptides and Proteins / metabolism. Keratin-7 / metabolism. Kidney / pathology. Male. Precancerous Conditions / enzymology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Rats. Rats, Inbred Lew. Rats, Sprague-Dawley. Signal Transduction. Streptozocin. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetologia. 1999 Jan;42(1):107-12 [10027588.001]
  • [Cites] Lab Invest. 1994 Nov;71(5):688-99 [7967522.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):119-26 [10755601.001]
  • [Cites] Diabetes. 1990 Dec;39(12):1490-7 [2174008.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):950-3 [7947103.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1249-56 [8644865.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):1071-87 [9060843.001]
  • [Cites] Gan. 1966 Dec;57(6):595-604 [5981257.001]
  • [Cites] Mol Carcinog. 1997 Jul;19(3):213-9 [9254888.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6993-7002 [15557196.001]
  • [Cites] Transplantation. 1994 Aug 15;58(3):349-54 [8053060.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1833-43 [16452245.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):303-13 [9387091.001]
  • [Cites] Toxicol Pathol. 1998 Nov-Dec;26(6):769-76 [9864094.001]
  • [Cites] Diabetologia. 2000 Oct;43(10):1205-23 [11079738.001]
  • [Cites] Diabetologia. 1990 Jun;33(6):334-8 [2199279.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Nature. 1967 Jun 17;214(5094):1254-5 [6066123.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):580-600 [11059863.001]
  • [Cites] Int J Cancer. 1995 Sep 4;62(5):501-7 [7665217.001]
  • [Cites] Trends Endocrinol Metab. 2006 Oct;17(8):328-36 [16956771.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):341-5 [9466558.001]
  • [Cites] APMIS. 1988 Aug;96(8):749-54 [3137943.001]
  • [Cites] J Am Soc Nephrol. 1997 Mar;8(3):436-44 [9071712.001]
  • [Cites] Carcinogenesis. 1992 Dec;13(12):2329-34 [1473241.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1974;81(3-4):311-31 [4372828.001]
  • [Cites] Lab Invest. 2000 Sep;80(9):1399-411 [11005208.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):506-11 [1434530.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(5):275-83 [2570488.001]
  • [Cites] Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1978 Aug 24;92(1):63-86 [151405.001]
  • [Cites] Semin Oncol. 1983 Dec;10(4):378-84 [6320450.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1029-33 [2543641.001]
  • [Cites] Adv Enzyme Regul. 1986;25:279-96 [2949538.001]
  • [Cites] Cancer Invest. 2005;23(3):240-55 [15945510.001]
  • [Cites] Am J Pathol. 1957 Nov-Dec;33(6):1035-57 [13478656.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):2089-94 [8952541.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8093-100 [15520221.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4182-7 [7664295.001]
  • [Cites] Clin Cancer Res. 1995 Aug;1(8):913-20 [9816062.001]
  • [Cites] Cancer Res. 1974 Jan;34(1):158-60 [4272120.001]
  • [Cites] Prog Histochem Cytochem. 1991;23(1-4):61-72 [1947168.001]
  • [Cites] Int J Urol. 2007 May;14(5):393-7 [17511719.001]
  • (PMID = 17952403.001).
  • [ISSN] 0012-186X
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Keratin-7; 5W494URQ81 / Streptozocin
  •  go-up   go-down


76. Zhang G, Fang L, Zhu L, Zhong Y, Wang PG, Sun D: Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia. J Med Chem; 2006 Mar 9;49(5):1792-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.
  • To overcome drug resistance, we synthesized a novel class of disaccharide analogues of DNR against drug-resistant leukemia.
  • Their cytotoxicities were examined in drug-sensitive leukemia cells K562 and doxorubicin-resistant K562/Dox cells by MTS assay.
  • In drug-sensitive cells, compounds 1-6 were found to be active against leukemia K562 cells with IC50 in the nanomolar range (200-1100 nM), while compounds 2-5 with 2,6-dideoxy sugars showed better activity than compounds 1 and 6 with 2,3,6-trideoxy sugars.
  • Structure-activity relationship (SAR) studies showed that the substitution and orientation of the 3-OH group in the second sugar significantly influence its activity against drug-resistant leukemia.
  • [MeSH-minor] Drug Screening Assays, Antitumor. Humans. K562 Cells. Leukemia, Erythroblastic, Acute

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509594.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Azides; 0 / Disaccharides; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


77. Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G: Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol; 2010 Jan;38(1):27-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Imatinib mesylate (IM) is a tyrosine kinase inhibitor selective for BCR-ABL and indicated for the treatment of chronic myeloid leukemia.
  • Considering the significant role of telomerase in malignant transformation, we studied the effect of IM on telomerase activity (TA) and regulation in BCR-ABL-positive and -negative cells, sensitive and resistant to IM.
  • MATERIALS AND METHODS: Through combining telomeric repeat amplification protocol for detecting TA, reverse transcription polymerase chain reaction and Western blots for detecting RNA and protein levels of telomerase regulating proteins and fluorescence-activated cell sorting analysis, we showed that IM targets telomerase and the signal transduction cascade upstream of it.
  • RESULTS: IM significantly inhibited TA in BCR-ABL-positive and -negative cells and in chronic myeloid leukemia patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Genes, abl. Leukemia, Erythroblastic, Acute / pathology. Piperazines / pharmacology. Pyrimidines / pharmacology. Signal Transduction / drug effects. Telomerase / antagonists & inhibitors

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837126.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA Primers; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


78. Pech D, Vidal-Martínez VM, Aguirre-Macedo ML, Gold-Bouchot G, Herrera-Silveira J, Zapata-Pérez O, Marcogliese DJ: The checkered puffer (Spheroides testudineus) and its helminths as bioindicators of chemical pollution in Yucatan coastal lagoons. Sci Total Environ; 2009 Mar 15;407(7):2315-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results from sediment analyses demonstrated the presence of hydrocarbons, organochlorine pesticides and polychlorinated biphenyls at varying concentrations, some of which exceeded the Probability Effect Level (PEL).

  • MedlinePlus Health Information. consumer health - Water Pollution.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135703.001).
  • [ISSN] 0048-9697
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Water Pollutants, Chemical; 059QF0KO0R / Water
  •  go-up   go-down


79. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP: Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res; 2010 Feb;30(2):319-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-eight-hour treatment of colon cancer HCT-116 and HT-29 cells with FOLFOX resulted in 60-70% survival, accompanied by a marked activation of insulin like growth factor-1 receptor (IGF-1R) and minor to moderate increase in epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2) as well as v-akt murine thymoma viral oncogene homolog 1 (AKT), cyclooxygenase-2 (COX-2) and cyclin-D1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Colonic Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / metabolism. Receptor, IGF Type 1 / metabolism

  • Hazardous Substances Data Bank. CURCUMIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 2;277(3):757-63 [11062025.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40 [12050094.001]
  • [Cites] Curr Pharm Des. 2002;8(19):1695-706 [12171541.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1191-204 [12360481.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6847-54 [15501961.001]
  • [Cites] Carcinogenesis. 1992 Nov;13(11):2183-6 [1423891.001]
  • [Cites] Carcinogenesis. 1993 Nov;14(11):2219-25 [8242846.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):259-66 [7812955.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2452-67 [8665853.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):365-73 [9060958.001]
  • [Cites] J Lab Clin Med. 1997 Dec;130(6):576-84 [9422331.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):597-601 [9973206.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):349-80 [15523106.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):278-87 [16170359.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):823-35 [16614884.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10100-11 [17047074.001]
  • [Cites] Int J Colorectal Dis. 2007 May;22(5):491-7 [16947041.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] Int J Cancer. 2008 Jan 15;122(2):267-73 [17918158.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):485-98 [19034632.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1951-7 [19244128.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1128-33 [10534157.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6013-20 [10557090.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):323-5 [10690506.001]
  • (PMID = 20332435.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG014343; United States / NIA NIH HHS / AG / R01 AG014343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / RNA, Small Interfering; 04ZR38536J / oxaliplatin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1; IT942ZTH98 / Curcumin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS521056; NLM/ PMC3836443
  •  go-up   go-down


80. Huang HF, Chen YZ, Wu Y: ZnPcS2P2-based photodynamic therapy induces mitochondria-dependent apoptosis in K562 cells. Acta Biochim Biophys Sin (Shanghai); 2005 Jul;37(7):488-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study investigated the mechanism underlying the killing effects of a novel amphipathic photosensitizer [di-sulfonated di-phthalimidomethyl phthalocyanine zinc (ZnPcS2P2)]-mediated photodynamic therapy (ZnPcS2P2-PDT) on K562 cells.
  • Furthermore, ZnPcS2P2-PDT down-regulated the expression of chimaeric Bcr-Abl oncoprotein, which is the molecular hallmark of chronic myelogenous leukemia (CML).
  • [MeSH-minor] Caspase 3. Caspases / biosynthesis. Cytochromes c / biosynthesis. DNA Fragmentation. Down-Regulation. Flow Cytometry. Fusion Proteins, bcr-abl / biosynthesis. Humans. In Situ Nick-End Labeling. Intracellular Membranes. K562 Cells. Leukemia, Erythroblastic, Acute / drug therapy. Membrane Potentials / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999210.001).
  • [ISSN] 1672-9145
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Indoles; 0 / Organometallic Compounds; 61569-01-5 / zinc phthalocyanine disulfonate; 9007-43-6 / Cytochromes c; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


81. García-Sacristán A, Fernández-Nestosa MJ, Hernández P, Schvartzman JB, Krimer DB: Protein kinase clk/STY is differentially regulated during erythroleukemia cell differentiation: a bias toward the skipped splice variant characterizes postcommitment stages. Cell Res; 2005 Jul;15(7):495-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase clk/STY is differentially regulated during erythroleukemia cell differentiation: a bias toward the skipped splice variant characterizes postcommitment stages.
  • Here we showed that clk/STY, as well as other members of the family (e.g. clk2, clk3 and clk4), are up-regulated during HMBA-induced erythroleukemia cell differentiation. mRNAs coding for the full-length and the truncated forms were responsible for the overall increased expression.
  • These results suggest that clk/STY might contribute to control erythroid differentiation by a mechanism that implicates a balance between these two isoforms.
  • [MeSH-major] Alternative Splicing. Cell Differentiation / physiology. Gene Expression Regulation, Enzymologic. Leukemia, Erythroblastic, Acute / enzymology. Protein-Serine-Threonine Kinases / metabolism. Protein-Tyrosine Kinases / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045812.001).
  • [ISSN] 1001-0602
  • [Journal-full-title] Cell research
  • [ISO-abbreviation] Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Acetamides; 0 / Isoenzymes; EC 2.7.1.- / Clk dual-specificity kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; LA133J59VU / hexamethylene bisacetamide
  •  go-up   go-down


82. Schnekenburger M, Morceau F, Henry E, Blasius R, Dicato M, Trentesaux C, Diederich M: Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells. Leuk Res; 2006 May;30(5):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over-expression of glutathione S-transferase P1 is related to chemotherapeutic drug resistance as well as to differentiation of human erythroleukemia cells.
  • In opposition to previously described differentiating inducers which enhance the GST-resistance phenotype, time- and concentration-dependent activation of both erythroid and megakaryocytic differentiation pathways by butyric acid progressively diminished GSTP1 mRNA expression.
  • [MeSH-major] Butyric Acid / pharmacology. Gene Expression Regulation, Enzymologic / drug effects. Glutathione S-Transferase pi / genetics. Transcription, Genetic

  • Hazardous Substances Data Bank. n-BUTYRIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213016.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 107-92-6 / Butyric Acid; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


83. Landon P, Breysse P, Chen Y: Noise exposures of rail workers at a North American chemical facility. Am J Ind Med; 2005 Apr;47(4):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peak and maximum sound levels were also recorded during each sampling period.
  • RESULTS: Full-shift noise exposures were all below the Occupational Safety and Health Administration's (OSHA) permissible exposure limit (PEL) and action level for a 12-hr workday.
  • Peak impact sound levels exceeded 140 dB in 17 of 18 samples (94%) with a mean peak sound level of 143.9 dB.
  • Maximum continuous sound levels were greater than 115 dBA in 4 of 18 samples (22%) with a mean maximum sound level of 113.1 dBA.
  • The source of peak impact sound levels was a daily exposure to a concussion caused by a sudden break in a freight airline.
  • Peak impact and maximum continuous sound levels can be attenuated through the use of hearing protection or by increasing distances from railroad noise sources.
  • [MeSH-major] Chemical Industry. Noise, Occupational. Occupational Exposure / analysis. Railroads

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15776466.001).
  • [ISSN] 0271-3586
  • [Journal-full-title] American journal of industrial medicine
  • [ISO-abbreviation] Am. J. Ind. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Hussain AR, Al-Jomah NA, Siraj AK, Manogaran P, Al-Hussein K, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S: Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res; 2007 Apr 15;67(8):3888-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is an incurable, aggressive B-cell malignancy that develops rapid resistance to conventional chemotherapy.
  • In efforts to identify novel approaches to block proliferation of PEL cells, we found that sanguinarine, a natural compound isolated from the root plant Sanguinaria canadendid, inhibits cell proliferation and induces apoptosis in a dose-dependent manner in several PEL cell lines.
  • Our data show that sanguinarine treatment of PEL cells results in up-regulation of death receptor 5 (DR5) expression via generation of reactive oxygen species (ROS) and causes activation of caspase-8 and truncation of Bid (tBid).
  • In addition, we show that pretreatment of PEL cells with carbobenzoxy-Val-Ala-Asp-fluoromethylketone, a universal inhibitor of caspases, abrogates caspase and PARP activation and prevents cell death induced by sanguinarine.
  • Moreover, treatment of PEL cells with sanguinarine down-regulates expression of inhibitor of apoptosis proteins (IAP).
  • Taken together, our findings suggest that sanguinarine is a potent inducer of apoptosis of PEL cells via up-regulation of DR5 and raise the possibility that this agent may be of value in the development of novel therapeutic approaches for the treatment of PEL.
  • [MeSH-minor] BH3 Interacting Domain Death Agonist Protein / metabolism. Caspases / metabolism. Cell Growth Processes / drug effects. Cell Line, Tumor. Collagen Type XI / metabolism. Cytochromes c / metabolism. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Exudates and Transudates / cytology. Humans. Isoenzymes / metabolism. Membrane Potential, Mitochondrial / drug effects. Mitochondria / drug effects. Mitochondria / metabolism. Mitochondria / physiology. Molecular Conformation. Reactive Oxygen Species / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / biosynthesis. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Signal Transduction / drug effects. Up-Regulation / drug effects. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440103.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / BAX protein, human; 0 / BH3 Interacting Domain Death Agonist Protein; 0 / BID protein, human; 0 / Benzophenanthridines; 0 / COL11A2 protein, human; 0 / Collagen Type XI; 0 / Isoenzymes; 0 / Isoquinolines; 0 / Reactive Oxygen Species; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / bcl-2-Associated X Protein; 9007-43-6 / Cytochromes c; AV9VK043SS / sanguinarine; EC 3.4.22.- / Caspases
  •  go-up   go-down


85. Kwok KW, Bjorgesaeter A, Leung KM, Lui GC, Gray JS, Shin PK, Lam PK: Deriving site-specific sediment quality guidelines for Hong Kong marine environments using field-based species sensitivity distributions. Environ Toxicol Chem; 2008 Jan;27(1):226-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As the construction of f-SSDs requires the use of a collection of responses from individual species to a chemical gradient in sediment, data screening criteria on the minimum abundance of the species were evaluated and optimized to ensure sufficient statistical power for estimating these responses.
  • The community-adjusted hazardous concentrations of 5% and 10% of the f-SSDs were adopted to represent the threshold effects level (TEL) and predicted effects level (PEL), respectively.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18092863.001).
  • [ISSN] 0730-7268
  • [Journal-full-title] Environmental toxicology and chemistry
  • [ISO-abbreviation] Environ. Toxicol. Chem.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Metals, Heavy; 0 / Polycyclic Hydrocarbons, Aromatic; DFC2HB4I0K / Polychlorinated Biphenyls
  •  go-up   go-down


86. Lehne G, Grasmo-Wendler UH, Berner JM, Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E, Myklebost O: Upregulation of stem cell genes in multidrug resistant K562 leukemia cells. Leuk Res; 2009 Oct;33(10):1379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of stem cell genes in multidrug resistant K562 leukemia cells.
  • We compared the genomic profile and gene expression pattern of the P-gp positive K562VCR cells with parental P-gp negative K562wt cells.
  • In K562VCR array CGH revealed amplification of ABCB1, ABCB4, ABCB5 and SEMA3D, whereas expression microarrays demonstrated upregulation of stem cell genes (e.g.
  • KIT and HOXB4), anti-apoptotic genes (e.g.
  • IGF1R and CCNG1), and downregulation of pro-apoptotic genes (e.g.
  • [MeSH-major] K562 Cells / pathology. Leukemia, Erythroblastic, Acute / genetics. P-Glycoprotein / genetics. P-Glycoproteins / genetics
  • [MeSH-minor] Chromosome Mapping. Chromosomes, Human. Flow Cytometry. Gene Expression Profiling. Homeodomain Proteins / genetics. Humans. Oligonucleotide Array Sequence Analysis. Stem Cell Factor / genetics. Stem Cells / cytology. Stem Cells / physiology. Transcription Factors / genetics. Up-Regulation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2009 Oct;33(10):1303-5 [19477512.001]
  • (PMID = 19394083.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCB5 protein, human; 0 / HOXB4 protein, human; 0 / Homeodomain Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Stem Cell Factor; 0 / Transcription Factors; 0 / multidrug resistance protein 3
  •  go-up   go-down


87. Voisin V, Legault P, Ospina DP, Ben-David Y, Rassart E: Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus. BMC Med Genomics; 2010 Jan 26;3:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.
  • BACKGROUND: Acute erythro- and megakaryoblastic leukaemias are associated with very poor prognoses and the mechanism of blastic transformation is insufficiently elucidated.
  • The murine Graffi leukaemia retrovirus induces erythro- and megakaryoblastic leukaemias when inoculated into NFS mice and represents a good model to study these leukaemias.
  • METHODS: To expand our understanding of genes specific to these leukaemias, we compared gene expression profiles, measured by microarray and RT-PCR, of all leukaemia types induced by this virus.
  • RESULTS: The transcriptome level changes, present between the different leukaemias, led to the identification of specific cancerous signatures.
  • We reported numerous genes that may be potential oncogenes, may have a function related to erythropoiesis or megakaryopoiesis or have a poorly elucidated physiological role.
  • The expression pattern of these genes has been further tested by RT-PCR in different samples, in a Friend erythroleukaemic model and in human leukaemic cell lines.We also screened the megakaryoblastic leukaemias for viral integrations and identified genes targeted by these integrations and potentially implicated in the onset of the disease.
  • CONCLUSIONS: Taken as a whole, the data obtained from this global gene profiling experiment have provided a detailed characterization of Graffi virus induced erythro- and megakaryoblastic leukaemias with many genes reported specific to the transcriptome of these leukaemias for the first time.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 May 15;67(10):4767-73 [17510405.001]
  • [Cites] Cancer Lett. 2007 Jul 8;252(1):36-42 [17215076.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] Blood. 2007 Jul 15;110(2):509-18 [17403918.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2361-70 [17548578.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep-Oct;1769(9-10):546-58 [17669516.001]
  • [Cites] Immunol Res. 2007;39(1-3):185-93 [17917065.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 23;363(3):462-5 [17904521.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5390-9 [18349318.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10907-12 [18669654.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2738-49 [18625887.001]
  • [Cites] Leukemia. 2009 Jan;23(1):95-103 [18830255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2659-64 [16533754.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Exp Hematol. 2000 Dec;28(12):1423-31 [11146164.001]
  • [Cites] Tohoku J Exp Med. 2000 Dec;192(4):259-73 [11286316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):451-5 [11398875.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):608-12 [11477115.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14458-63 [11734646.001]
  • [Cites] Haematologica. 2002 Feb;87(2):148-53 [11836165.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):213-24 [11864595.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1399-401 [12145675.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):205-10 [12490656.001]
  • [Cites] Am J Hematol. 2003 Jun;73(2):71-80 [12749007.001]
  • [Cites] J Biol Chem. 2003 Jul 4;278(27):24705-13 [12716902.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7 [14681473.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):11-24 [14725896.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2062-70 [14630787.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):47-52 [15201957.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1306-13 [15138166.001]
  • [Cites] Trends Immunol. 2004 Sep;25(9):489-95 [15324742.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(16):5455-9 [3860871.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):460-2 [2411180.001]
  • [Cites] Br J Haematol. 1986 Feb;62(2):287-92 [3947550.001]
  • [Cites] EMBO J. 1989 Jan;8(1):133-6 [2653809.001]
  • [Cites] Leukemia. 1990 Aug;4(8):590-4 [2143796.001]
  • [Cites] Blood. 1993 Nov 15;82(10):2998-3004 [8219191.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1284-96 [8695846.001]
  • [Cites] Stem Cells. 1996 Jan;14(1):117-23 [8820957.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24300-7 [9305885.001]
  • [Cites] Vet Pathol. 1997 Sep;34(5):463-6 [9381658.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6187-92 [9600939.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1335-7 [9753066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] J Virol. 1999 May;73(5):4439-42 [10196342.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2812-22 [10329627.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5525-34 [10523829.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3136-47 [15297311.001]
  • [Cites] Blood. 2005 Jan 1;105(1):405-9 [15191953.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):11-20 [15630411.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1220-30 [15580294.001]
  • [Cites] Immunol Cell Biol. 2005 Apr;83(2):196-8 [15748217.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):351-60 [15767544.001]
  • [Cites] EMBO J. 2005 Jun 1;24(11):1976-87 [15889140.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2147-55 [15914564.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):902-11 [16156860.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2417-23 [15961512.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18968-73 [16365299.001]
  • [Cites] Leuk Res. 2006 Apr;30(4):397-406 [16219351.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1857-63 [16254139.001]
  • [Cites] Cell Immunol. 2005 Nov;238(1):1-9 [16442516.001]
  • [Cites] Gene. 2006 Mar 1;368:1-11 [16314052.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6874-83 [16407276.001]
  • [Cites] Acta Pharmacol Sin. 2006 Apr;27(4):387-94 [16539836.001]
  • [Cites] J Virol. 2006 Apr;80(8):4026-37 [16571819.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):12081-92 [16497666.001]
  • [Cites] Virology. 2006 Sep 1;352(2):306-18 [16780917.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(2):127-37 [16791477.001]
  • [Cites] Circ Res. 2007 Jan 5;100(1):27-40 [17204662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1236-41 [17229837.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1451-9 [17047147.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2486-98 [17261592.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):104-10 [17475220.001]
  • (PMID = 20102610.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP-37994; Canada / Canadian Institutes of Health Research / / MOP-84460
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2843641
  •  go-up   go-down


88. Yiakoumis X, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Kontopidou FN, Kalpadakis C, Korkolopoulou P, Levidou G, Androulaki A, Siakantaris MP, Sachanas S, Andreopoulos A: Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy. Anticancer Res; 2010 Jan;30(1):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) mostly occurring in HIV-positive patients.
  • We report two HIV-negative, HHV8-positive patients with PEL of the pleural cavity who achieved a durable remission after pleurodesis with bleomycin and no systemic therapy.
  • We also perform a review of the relevant literature regarding the clinical data, treatment, and survival of PEL in HIV-negative patients.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150647.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


89. Nakanishi T, Shiozawa K, Hassel BA, Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood; 2006 Jul 15;108(2):678-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies of the mechanism of the diminished resistance to imatinib compared with mitoxantrone revealed that imatinib decreased the expression of BCRP in K562/BCRP-MX10 cells without affecting mRNA levels.
  • BCRP levels in cells that do not express BCR-ABL were not affected by imatinib.
  • The phosphoinositol-3 kinase (PI3K) inhibitor LY294002 also decreased BCRP levels in K562/BCRP-MX10 cells.
  • These studies show that BCRP causes measurable imatinib resistance, but this effect is attenuated by imatinib-mediated inhibition of BCR-ABL, which in turn downregulates overall BCRP levels posttranscriptionally via the PI3K-Akt pathway.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl. Leukemia, Erythroblastic, Acute / pathology. Neoplasm Proteins / metabolism. Piperazines / pharmacology. Pyrimidines / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543472.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Benzamides; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; BZ114NVM5P / Mitoxantrone; CW5S8OP3VO / tryptoquivaline; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


90. Juban G, Giraud G, Guyot B, Belin S, Diaz JJ, Starck J, Guillouf C, Moreau-Gachelin F, Morlé F: Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells. Mol Cell Biol; 2009 May;29(10):2852-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells.
  • Spi-1 and Fli-1 are ETS transcription factors recurrently deregulated in mouse erythroleukemia induced by Friend viruses.
  • Since they share the same core DNA binding site, we investigated whether they may contribute to erythroleukemia by common mechanisms.
  • Among these additively downregulated transcripts, more than 20% encode proteins involved in ribosome biogenesis, and conserved ETS binding sites are present in their gene promoters.
  • [MeSH-major] Friend murine leukemia virus / metabolism. Leukemia, Erythroblastic, Acute. Peptides / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism. Ribosomes / metabolism. Tumor Cells, Cultured / physiology
  • [MeSH-minor] Animals. Apoptosis / physiology. Cell Proliferation. Gene Expression Regulation. Gene Knockdown Techniques. Humans. Mice. Phenotype

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7654-68 [15314173.001]
  • [Cites] Nucleic Acids Res. 2004;32(14):4358-67 [15314206.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Jun;75(6):2795-9 [275849.001]
  • [Cites] Exp Hematol. 1985 Aug;13(7):610-5 [3861324.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1383-93 [9028962.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5639-53 [9312023.001]
  • [Cites] Oncogene. 1998 Jun 11;16(23):2989-95 [9662331.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):121-35 [9858537.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1597-608 [10102630.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3257-66 [10207051.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4452-64 [10330185.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1398-411 [10364157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10 [10411939.001]
  • [Cites] Histopathology. 2005 Feb;46(2):202-8 [15693893.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1288-92 [15766566.001]
  • [Cites] BMC Evol Biol. 2005;5:15 [15707503.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] EMBO J. 2005 Nov 2;24(21):3712-23 [16222338.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2462-78 [16213704.001]
  • [Cites] J Virol. 2005 Dec;79(23):14586-94 [16282458.001]
  • [Cites] Mass Spectrom Rev. 2006 Mar-Apr;25(2):215-34 [16211575.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jul;132(7):417-26 [16456675.001]
  • [Cites] EMBO J. 2006 Nov 29;25(23):5614-25 [17110929.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):19-32 [17143509.001]
  • [Cites] Cell Cycle. 2007 Feb 15;6(4):434-7 [17329973.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8052-9 [17242401.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3007-14 [17132716.001]
  • [Cites] Genes Dev. 1987 Oct;1(8):855-61 [3480842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(4):1332-6 [2304901.001]
  • [Cites] Cell. 1991 Sep 6;66(5):831-4 [1889087.001]
  • [Cites] Mol Cell Biol. 1992 Jul;12(7):2967-75 [1620109.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1089-109 [10582341.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2543-51 [10753833.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2296-304 [10822380.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6482-9 [11175364.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):694-703 [11847117.001]
  • [Cites] Oncogene. 2002 May 16;21(22):3562-70 [12032858.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2929-41 [8474451.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1723-7 [8183568.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2453-63 [8628313.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3385-91 [8631937.001]
  • [Cites] Oncogene. 1997 Jan 9;14(1):123-31 [9010239.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3839-3854 [17353275.001]
  • [Cites] Genome Res. 2007 Jun;17(6):798-806 [17567998.001]
  • [Cites] Genes Dev. 2007 Aug 1;21(15):1882-94 [17652178.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5029-37 [17310983.001]
  • [Cites] Mol Cell. 2007 Aug 17;27(4):573-84 [17707229.001]
  • [Cites] Blood. 2007 Dec 1;110(12):3871-80 [17715392.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10 [18245377.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):497-511 [18563191.001]
  • [Cites] Am J Pathol. 2008 Aug;173(2):301-10 [18583314.001]
  • [Cites] PLoS Genet. 2008;4(7):e1000133 [18654640.001]
  • [Cites] Cell Mol Life Sci. 2008 Aug;65(15):2334-59 [18408888.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5348-53 [18542058.001]
  • [Cites] J Cell Biochem. 2008 Oct 15;105(3):670-7 [18773413.001]
  • [Cites] Oncogene. 2008 Oct 2;27(44):5774-84 [18560357.001]
  • [Cites] BMC Genomics. 2008;9:442 [18816399.001]
  • [Cites] Nature. 2008 Dec 18;456(7224):971-5 [19011615.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1390-402 [12556498.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2159-66 [12894591.001]
  • [Cites] Gene. 2003 Aug 14;313:17-42 [12957375.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6363-9 [14559825.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7460-74 [14559995.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4555-62 [12946994.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2993-3002 [14570912.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • (PMID = 19289502.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / Proto-Oncogene Protein c-fli-1; 129712-62-5 / lambda Spi-1
  • [Other-IDs] NLM/ PMC2682047
  •  go-up   go-down


91. Hasegawa H, Chatterjee A, Cui Y, Chatterjee AK: Elevated temperature enhances virulence of Erwinia carotovora subsp. carotovora strain EC153 to plants and stimulates production of the quorum sensing signal, N-acyl homoserine lactone, and extracellular proteins. Appl Environ Microbiol; 2005 Aug;71(8):4655-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Erwinia carotovora subsp. atroseptica, E. carotovora subsp. betavasculorum, and E. carotovora subsp. carotovora produce high levels of extracellular enzymes, such as pectate lyase (Pel), polygalacturonase (Peh), cellulase (Cel), and protease (Prt), and the quorum-sensing signal N-acyl-homoserine lactone (AHL) at 28 degrees C.
  • At elevated temperatures these bacteria produce high levels of RsmA, an RNA binding protein that promotes RNA decay. E. carotovora subsp. carotovora strain EC153 is an exception in that it produces higher levels of Pel, Peh, Cel, and Prt at 34.5 degrees C than at 28 degrees C.
  • EC153 also causes extensive maceration of celery petioles and Chinese cabbage leaves at 34.5 degrees C, which correlates with a higher growth rate and higher levels of rRNA and AHL.
  • The lack of pectinase production by E. carotovora subsp. carotovora strain Ecc71 at 34.5 degrees C limits the growth of this organism in plant tissues and consequently impairs its ability to cause tissue maceration.
  • Comparative studies with ahlI (the gene encoding a putative AHL synthase), pel-1, and peh-1 transcripts documented that at 34.5 degrees C the RNAs are more stable in EC153 than in Ecc71.
  • Our data reveal that overall metabolic activity, AHL levels, and mRNA stability are responsible for the higher levels of extracellular protein production and the enhanced virulence of EC153 at 34.5 degrees C compared to 28 degrees C.
  • [MeSH-major] 4-Butyrolactone / analogs & derivatives. Gene Expression Regulation, Bacterial. Pectobacterium carotovorum / enzymology. Pectobacterium carotovorum / pathogenicity. Temperature

  • Hazardous Substances Data Bank. BUTYROLACTONE .
  • [Email] Email this result item
    Email the results to the following email address: